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2 Abstract 
2 ABSTRACT 
Analgesic effects of opioids are mediated by opioid receptors that are widely distributed in the 
central and peripheral nervous systems (CNS and PNS, respectively). Although opioids are 
the most powerful analgesics, severe side effects restrict their use and affect patient 
convalescence. These side effects, for example respiratory depression, sedation or 
dependence, are mediated by the activation of central opioid receptors. This suggests an 
advantage of new analgesic opioids which selectively bind to opioid receptors in the PNS 
with no access to opioid receptors in the CNS due to a restricted ability to permeate the blood 
brain barrier. In clinical practice, oral administration of analgesic drugs is preferred to avoid 
discomfort to the patient. After oral administration however, peripherally restricted opioids 
first have to cross the intestinal epithelial barrier before absorption into the circulation and 
distribution to opioid receptors in peripheral tissues. Here, the transport across intestinal 
epithelia of two opioid ligands that selectively activate peripheral opioid receptors without 
entering the CNS, the hydrophilic morphinan AS006 and the lipophilic piperidine derivative 
loperamide were investigated. To increase the intestinal passage of these drugs, the absorption 
enhancer chitosan was used. 
In vitro transport studies were performed using confluent monolayers of two human intestinal 
epithelial colon cell lines, HT29/B6 and Caco-2, in Ussing chambers. AS006 and loperamide 
that passed epithelial monolayers were determined using a liquid chromatography coupled 
with tandem mass spectrometry method established in the first part of this study. Chitosan 
significantly decreased the transepithelial resistance of both cell lines after 30 min in vitro. 
The permeability values for AS006 increased from < 0.3 × 10-6 cm/s up to 10 × 10-6 cm/s in 
the presence of chitosan. In contrast, HT29/B6 monolayers showed moderate loperamide 
permeability in the presence of chitosan, and chitosan had no effect on the permeability of 
loperamide using Caco-2 monolayers.  
In vivo studies focused on antinociceptive effects of loperamide alone or in combination with 
chitosan. These effects were analyzed using the paw pressure test in a model of inflammatory 
pain in rats. Oral administration of loperamide induced a dose-depended elevation of paw 
pressure thresholds in inflamed paws that lasted for 60 min. This effect was comparable to 
that of intravenously applied loperamide. Oral administration of loperamide combined with 
chitosan slightly but nonsignificantly enhanced the antinociceptive effect of loperamide.  
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2 Abstract 
In conclusion, chitosan is a suitable absorption enhancer for in vitro intestinal permeability 
studies. Epithelial permeability enhancement by chitosan appears to be more effective for 
hydrophilic opioids (AS006) than for lipophilic ones (loperamide). Future in vivo experiments 
might investigate different formulations and application schedules, and further address the 
effects of chitosan on the antinociceptive efficacy of hydrophilic opioids.   
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3 Zusammenfassung 
3 ZUSAMMENFASSUNG 
Die schmerzstillende Wirkung von Opiaten wird über Opioidrezeptoren im zentralen und 
peripheren Nervensystem (ZNS und PNS) vermittelt. Die Schmerzlinderung kann jedoch mit 
sehr starken Nebenwirkungen einhergehen, die das Patientenwohlbefinden beeinträchtigen. 
Nebenwirkungen wie Atemdepression, Sedierung oder Abhängigkeit werden durch die 
Aktivierung von zentralen Opioidrezeptoren vermittelt. Dies legt die Bedeutung von neuen 
Opioidanalgetika nahe, die ihre schmerzstillende Wirkung ausschließlich über 
Opioidrezeptoren im PNS entfalten, ohne unerwünschte zentrale Nebenwirkungen zu 
induzieren. Die orale Gabe von Medikamenten minimiert Unannehmlichkeiten für den 
Patienten, jedoch müssen die Substanzen die intestinale Barriere passieren können, um in die 
Blutzirkulation eintreten zu können.  
Die intestinale Permeabilität von zwei peripher wirksamen Opiaten, dem hydrophilen 
Morphinderivat AS006 und dem lipophilen Piperidinderivat Loperamid, wurde in Ussing-
Kammer Experimenten untersucht. Für diese in vitro Studien wurden zwei humane 
Darmzelllinien (HT29/B6 und Caco-2 Zellen) genutzt. Um die Darmepithelpermeabilität für 
beide Opiate zu erhöhen, wurde der Absorptionsverstärker Chitosan verwendet. Im Rahmen 
dieser Studie wurden für die Bestimmung der Konzentration von AS006 und Loperamid zwei 
neue LC-MS/MS Methoden entwickelt, validiert und angewendet. 
Chitosan bewirkte nach 30 Minuten bei beiden Zelllinien eine Abnahme des epithelialen 
Widerstands in vitro. Die Permeabilität für AS006 war bei beiden Zelllinien erhöht, für 
Loperamid nur bei HT29/B6, jedoch nicht bei Caco-2 Zellmonolayern.  
Verhaltensexperimente zur Messung des antinozizeptiven Effektes von oral appliziertem 
Loperamid auf Entzündungsschmerz wurden an Ratten durchgeführt. Die orale Gabe von 
Loperamid induzierte eine Dosis-abhängige antinozizeptive Wirkung in der entzündeten 
Hinterpfote, die vergleichbar mit der Wirkung von Loperamid nach intravenöser Gabe ausfiel. 
Bei oraler Gabe von Loperamid in Kombination mit Chitosan wurde keine signifikante 
Verstärkung des maximalen antinozizeptiven Effekts von Loperamid beobachtet.  
Zusammenfassend ist Chitosan ein geeigneter Absorptionsverstärker für intestinale 
Permeabilitätsstudien von peripher wirksamen Opioidanalgetika in vitro. Die in vitro 
Ergebnisse haben gezeigt, dass der Effekt von Chitosan auf lipophile Opiate (Loperamid) 
möglicherweise schwächer ist als auf hydrophile (AS006). Dementsprechend fiel die Wirkung 
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3 Zusammenfassung 
des Absorptionsverstärkers auf Loperamid-induzierte Analgesie im Verhaltensversuch eher 
gering aus. Die in vitro Wirkung von Chitosan auf den Transport von hydrophilen peripher 
wirkenden Opioiden (AS006) war jedoch signifikant und sollte in weiteren Studien untersucht 
werden. 
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4 Introduction 
4 INTRODUCTION 
4.1 Pain and opioids 
Pain is defined by the International Association for the Study of Pain (IASP) as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage” (IASP, 1979). Pain perception is always 
subjective and is influenced by individual experiences related to injuries in previous phases of 
life. In most cases, pain is accompanied by suffering of the individual. Nevertheless, acute 
pain perception prevents additional tissue damage and can be lifesaving. In 1983, Dennis and 
Melzack (Dennis and Melzack, 1983) postulated three purposes of pain: 
1) Short-lasting pain causes us to withdraw from the source, often reflexively, thus 
preventing further damage. 
2) Long-lasting pain promotes behaviors such as sleep, inactivity, grooming, feeding, and 
drinking that promote recuperation. 
3) The expression of pain serves as a social signal to other animals. For example, 
screeching after a painful stimulus signals the potential harm to genetically related 
individuals, and elicits caregiving behavior from them, such as grooming, defending, 
and feeding. 
Pain perception is mediated via nociceptors which are high-threshold neurons of the 
peripheral somatosensory nervous system. They are able to transduce and encode noxious 
stimuli (IASP, 1979) and send information first to the dorsal root ganglion and further onto 
the spinal cord and, via the ascending pathways to the brain (thalamus, somatosensory cortex 
and other parts of the cortex) for interpretation and response (Dobrila-Dintinjana and 
Nacinović-Duletić, 2011), as shown in Fig. 1. Nociceptors are found in skin, tendons, joints, 
muscles, and other organs and consist of A-delta and C fibers (Messlinger, 1997). For the 
induction of pain the noxious stimulus has to reach a certain threshold. Pain can be 
categorized into two classes; acute and chronic pain. Acute pain fulfills a warning role 
whereas chronic pain, which includes inflammatory, cancer and neuropathic pain, has no 
biological function (Millan, 1999).  
Opioids are powerful drugs to treat severe pain (IASP, 1979; Ripamonti et al., 2011). Opioids 
are classified by the World Health Organization (WHO) according to their ability to control 
mild to moderate pain (e.g. codeine, dihydrocodeine, tramadol) or moderate to severe pain 
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(e.g. morphine, methadone, oxycodone, fentanyl) (WHO, 1996). In addition, non-opioid 
analgesics like paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin 
and ibuprofen are used (McNicol et al., 2005). The long-term usage of NSAIDs has to be 
monitored due to their side effects like gastrointestinal bleeding and renal insufficiency 
(Ripamonti, 2012).     
 
 
 
 
 
 
 
 
Figure 1: Pain transmission pathway from the periphery to the central nervous system. A nociceptive 
stimulus (injury) activates peripheral nociceptors leading to the sensation of pain (modified after McDougall, 
2011). 
For the classification of pain in humans, standardized scales such as the visual analogue 
scales, verbal rating scale, and the numerical rating scale are used (Caraceni et al., 2002). For 
pain studies in animals different pain detection models have been established, due to the lack 
of verbal communication. Nociceptive tests use electrical, thermal, mechanical, or chemical 
stimuli for analysis of pain behavior (Le Bars et al., 2001). Nociceptive tests in rodents are 
summarized by Barrot (Barrot, 2012). The most common are the formalin test (Ko et al., 
2012), von Frey test (Chaplan et al., 1994), hot plate test (de Sá et al., 2012), tail flick test 
(Aydin et al., 2012), hargreaves test (Saika et al., 2012) and the paw pressure test (Brack et 
al., 2004a).  
The treatment of pain with opioids has a long history. The first written records describing the 
production and usage of morphine as a pharmaceutical compound go back to 4000 BC. These 
days morphine, codeine, fentanyl and oxycodone are the most powerful drugs to relieve 
severe pain (Spetea et al., 2004) by activation of opioid receptors in the CNS and PNS, 
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4 Introduction 
respectively (Ossipov et al., 2004; Yaksh and Rudy, 1978). Pain relief is mediated via the 
three classical opioid receptors: μ, δ and κ, which belong to the family of seven-
transmembrane G-protein-coupled receptors (van Rijn et al., 2010). The signal pathways 
activated after agonist binding to opioid receptors are well characterized. First, the opioid 
binds to a binding pocket within the receptor. After binding, conformational changes allow 
intracellular coupling of heterotrimeric Gi/o proteins to the C terminus of the receptor. GTP 
replaces GDP in the Gα subunit which results in dissociation of the trimeric G protein 
complex into Gα and Gβγ subunits. Hereafter the Gα subunit inhibits the synthesis of cyclic 
adenosine monophosphate (cAMP). Gβγ subunits interact directly with Ca2+ channels, the 
transient receptor potential vanilloid type 1 or other ion channels in the membrane (Endres-
Becker et al., 2007; Stein and Zöllner, 2009), as shown in Fig. 2. As a consequence, opioid 
agonists reduce the excitability of nociceptive neurons and the release of the pronociceptive 
neuropeptides (e.g. substance P and calcitonin gene-related peptide) from central and 
peripheral neuronal terminals.  
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Figure 2: Intracellular signaling pathways of the μ-opioid receptor.  
1. Agonist binds to opioid receptor. 2. Agonist binding to the receptor induces an exchange of GDP by 
GTP on the trimeric G protein complex which then dissociates from the receptor; the α subunit also 
dissociates from the β/γ subunits. 3. The GTP-bound α subunit inhibits the enzyme adenylyl cyclase 
leading to a decrease in intracellular cAMP concentrations. 4. The β/γ subunits activate potassium 
channels and inhibit voltage-sensitive calcium channels. As a result, the neuronal excitability and 
neurotransmitter release is attenuated. 
Usage of centrally active drugs like morphine can come along with undesirable side effects 
such as respiratory depression, nausea, mental clouding, addiction, and tolerance 
(MacPherson, 2002; Nicholson, 2003; Zöllner and Stein, 2007). These side effects are 
mediated through opioid receptor binding in the CNS. Opioid receptors are expressed in the 
CNS (Pert and Snyder, 1973) and PNS (Stein, 1993; Stein et al., 1988a), as well as in non-
neuronal cells such as immune and ectodermal cells (Zöllner and Stein, 2007). Under 
inflammatory conditions, peripheral opioid receptors on sensory neurons are upregulated 
(Stein et al., 2001). Activation of such peripheral opioid receptors can reduce pain both in 
humans (analgesia) (Khoury et al., 1990; Meiser and Laubenthal, 1997) and in animals 
(antinociception) (Rittner and Brack, 2007; Stein and Zöllner, 2009; Stein et al., 2003). 
In contrast to the parenteral route, which bears the risk of infection and needs to be conducted 
by specialized staff, oral drug administration is simple and minimize discomfort to the patient 
(Hans, 2007; Hurst et al., 2007; Thomas et al., 2006).  
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Thus, there is a need for opioids which selectively activate peripheral opioid receptors and can 
be administered orally.  
To synthesize peripherally acting opioids, the chemical structure of conventional opiates has 
been modified, for example to increase hydrophilicity which blocks passage into the CNS 
(DeHaven-Hudkins and Dolle, 2004). In addition, lipophilic compounds can be substrates of 
efflux membrane transporters like P-glycoprotein (P-gp), which is located in endothelial cells 
of the blood-brain barrier and in epithelial cells of the intestinal barrier (Crowe and Wong, 
2003). The combined introduction of hydrophilic and hydrophobic chemical characteristics 
has been shown to result in analgesic compounds (e.g. the κ agonist asimadoline, EMD 
61753) with restricted access to the CNS (Machelska et al., 1999). In a rat model of short-
lasting inflammation EMD 61753 produced dose-dependent, naloxone-reversible 
antinociception after systemic administration (Barber et al., 1994). Additionally, an 
antiarthritic action of EMD 61753 has been shown in polyarthritic rats after oral 
administration (Binder and Walker, 1998), but in humans undergoing, knee surgery, orally 
given EMD 61753 had no effect on postoperative pain (Machelska et al., 1999).  
However, increased hydrophilicity not only inhibits the transport across endothelial cell 
membranes of the blood-brain barrier, it would also restrict absorption through the intestinal 
epithelial barrier into the circulation (Matsuhisa et al., 2009). Thus, modulation of drug 
passage through the intestinal epithelial barrier is required to improve oral delivery of such 
compounds. This may be achieved by absorption enhancers which are exclusively acting on 
intestinal epithelial cells. 
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4.2 Intestinal barrier and tight junctions 
Tight junctions (TJs) represent the main component of the barrier formed by the intestinal 
epithelium. This barrier determines the paracellular movement of solutes between the 
functionally external compartments, including the intestinal lumen, and the internal 
compartments of the intestinal wall, including the blood vessels. TJs are localized in the 
apicolateral membrane of epithelial cells and organized in strands. Within these strands, four 
types of transmembrane proteins have been identified: occludin (Furuse et al., 1993), claudins 
(González-Mariscal et al., 2003), tricellulin (Ikenouchi et al., 2005) and junctional adhesion 
molecules (JAM) (Martìn-Padura et al., 1998). Occludin, claudins and tricellulin bear four 
transmembrane domains, two extracellular domains, and their amino and carboxyl terminal 
ends are oriented towards the intracellular region (González-Mariscal et al., 2003). They are 
known to determine paracellular barrier properties (Furuse et al., 1993, 1998; Ikenouchi et al., 
2005). In contrast, JAM have just one transmembrane region and are not only localized in TJ 
of epithelial and endothelial cells, but also expressed in leukocytes (Martìn-Padura et al., 
1998). Tricellulin is localized in tricellular TJs, the meeting points of three epithelial cells 
(Ikenouchi et al., 2005). Trans-interaction between the extracellular domains of those proteins 
closes the cleft between neighbouring cells. On the intracellular side, the transmembrane 
proteins are connected to the actin cytoskeleton via adaptor proteins such as zona occludens 
(ZO) 1, 2, and 3 (Aktories and Barbieri, 2005) as shown in Fig. 3. The expression of TJ 
proteins influences the local barrier properties and differs between organs and tissues 
(Amasheh et al., 2011; Markov et al., 2010).  
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Figure 3: TJ protein distribution in intestinal epithelial cells. 
TJs represent the main barrier of the intestinal epithelium by closing the paracellular cleft between two 
adjacent epithelial cells. Components of the cytoplasmic region underlying the TJ (“cytosolic plaque”) 
are built by transmembrane (occludin, claudins and junctional adhesion molecules, JAMs), and 
scaffolding proteins (ZO1, ZO2, ZO3, MUPP1, and MAGI). ZO proteins directly interact with 
occludins and claudins; via their C-terminus they are connected with the actin cytoskeleton. MUPP1 
and MAGI can directly interact with one or more of the transmembrane components (modified after 
Aktories and Barbieri, 2005; Niessen, 2007).  
In addition to the paracellular pathway, the intestinal barrier can be crossed via the 
transcellular route and through leaky areas caused by apoptosis, as summarized in Fig. 4. For 
transcellular passage, hydrophobic substances can be delivered passively by diffusion into the 
cell membrane (Watts and Fasano, 2000). Active transcellular passage is energy dependent 
and substrate specific, involving transporters like the intestinal oligopeptide transporter 
(PepT1) or P-gp in the cell membrane (Majumdar et al., 2004; Mizuno et al., 2003; Rosenthal 
et al., 2012a). PepT1 catalyzes electrogenic peptide transport by coupling of substrate 
translocation to the cotransport of H+ with the transmembrane electrochemical proton gradient 
providing the driving force (Döring et al., 1998). PepT1 recognizes therapeutics such as beta-
lactam antibiotics and 5-aminolevulinic as substrates (Amasheh et al., 1997; Döring et al., 
1998). P-gp is an adenosine triphosphate (ATP)-dependent transporter. Its activation leads to 
an active efflux of substrates from the cells. Opioids like morphine (King et al., 2001; 
Tight junction 
proteins 
Paracellular 
transport 
18 
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Schinkel et al., 1996a; Thomas et al., 2006), asimadoline (Jonker et al., 1999), and loperamide 
(Callaghan and Riordan, 1993; Huwyler et al., 1998), as well as a broad variety of peptides 
(Ganapathy and Miyauchi, 2005) are substrates of P-gp. 
  
 
Figure 4: The four intestinal transepithelial pathways: A: transcellular passive transport (limited to small 
molecules like amino acids and sugars), B: transcellular active transport (hydrophobic compounds), C: 
paracellular transport (drugs and vaccines), D: local leaks caused by apoptosis (modified after Rosenthal et al., 
2012a; Watts and Fasano, 2000).  
 
To increase the paracellular passage of macromolecules, TJs have to be modified. In vitro 
studies on intestinal permeability were mostly conducted with the epithelial human colon cell 
lines Caco-2 and HT29/B6 (Amasheh et al., 2012; Kowalik et al., 2004; Kreusel et al., 1991; 
Merzlikine et al., 2009; Moran et al., 2012; Press and Di Grandi, 2008). They form polarized, 
confluent monolayers, and develop microvilli and TJs between adjacent cells. HT29/B6 cells 
are Cl--secreting and mucus producing cells while Caco-2 cells have minor Cl--secreting and 
mucus producing properties (Hayslett et al., 1987; Hidalgo et al., 1989; Kreusel et al., 1991; 
Sun et al., 2008). They also differ in TJ protein expression patterns. HT29/B6 express 
claudin-5 in colocalization with occludin, whereas Caco-2 cells show a marginal or no 
expression of claudin-2 and -5 (Amasheh et al., 2005; Escaffit et al., 2005). 
  
                 A            B       C                      D 
intestinal lumen (apical side) 
blood (basolateral side) 
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4.3 Absorption enhancers 
The first attempts to increase drug passage via the paracellular pathway using absorption 
enhancers date back to the 1980s. Absorption enhancers can directly act on TJs and open the 
paracellular pathway for orally administered pharmaceutical compounds. The opening of TJs 
results in a drop of the transepithelial electrical resistance (TER), which is due to a higher 
passage of ions through the paracellular space. The TER is an indicator of how tightly 
adjacent epithelial cells are connected and thereby affect paracellular transport. 
A variety of molecules has been tested with respect to their properties to increase the 
permeability of intestinal epithelia. These molecules include surfactants, calcium chelating 
agents, fatty acids, medium chain glycerides, chitosans, steroidal detergents and, cyclodextrin 
(Aungst, 2000). Only sodium caprate is currently used as an absorption enhancer in 
pharmacological therapy as a component of a rectal ampicillin suppository (Kondoh et al., 
2005; Lindmark et al., 1997). Sodium caprate induces a remarkable drop in TER, which is 
reversible and associated with the transient dissociation of tricellulin from TJs (Krug et al., 
2013). 
Another well described enhancer is chitosan, which is produced by deacetylation of the 
second most abundant natural polymer chitin (Fig. 5).  
 
 
Figure 5: Basic chemical structure of low molecular weight chitosan. Molecular weight 50 – 190 kDa.  
Due to its pKa of 5.5 - 7.0 it is most efficient in solvents with a pH lower than 7 (Kotzé et al., 
1998, 1999; Rosenthal et al., 2012b). Chitosan is a biocompatible, antibacterial and 
environmentally friendly polyelectrolyte lending itself to a variety of applications (Kobayashi 
et al., 1996) including water treatment, chromatography, additives for cosmetics, textile 
treatment for antimicrobial activity (Shin et al., 1999), novel fibers for textiles, photographic 
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papers, biodegradable films (Hirano, 1996), decorporation of radioactive substances 
(Levitskaia et al., 2009), scaffolds for bone marrow mesenchymal stem cells (Cho et al., 
2008), biomedical devices, and microcapsule implants for controlled release in drug delivery 
(Bartkowiak and Hunkeler, 1999; Sezer and Akbuğa, 1999; Sonaje et al., 2009; Suzuki et al., 
1999). It affects different kinds of barriers including dermal (Valenta and Auner, 2004), nasal 
(Casettari et al., 2010; Luppi et al., 2010; Valenta and Auner, 2004), ocular (Alonso and 
Sánchez, 2003; Paolicelli et al., 2009; Wadhwa et al., 2009), pulmonary (Davis, 1999), and 
gastrointestinal epithelia (Chopra et al., 2006; Masuda et al., 2012; Thanou et al., 2001a).  
Chitosan induces a decrease in the paracellular resistance of intestinal epithelial cells by 
opening the TJs via interaction between the positively charged amino groups of the chitosan 
molecule with the negatively charged surface proteins of the TJ (Aungst, 2000; Borchard et 
al., 1996). In HT29/B6 cells, chitosan affects both transcellular (Rtrans) and paracellular (Rpara) 
resistance parameters via its positive charge. The decrease in Rtrans can be explained by 
activation of a chloride-bicarbonate exchanger involved in intracellular pH regulation, while 
no effects on expression and subcellular distribution of HT29/B6 TJ proteins or the actin 
cytoskeleton were found (Rosenthal et al., 2012b). 
In addition, chitosan can activate the protein kinase C α (PKC α) signaling pathway which 
catalyzes the phosphorylation of target protein(s) followed by the reorganization of the actin 
cytoskeleton. This leads to the polymerization of soluble G-actin into F-actin and causes a 
rearrangement of actin filaments followed by the displacement of proteins (including ZO1 and 
ZO2) from the junctional complex. The delocalization of the junctional complex opens the 
paracellular space between adjacent intestinal epithelial cells (Fasano, 1999, 2001; Smith et 
al., 2004). It has been shown that chitosan is involved in dissociation of claudin 4 and 
claudin 1 in the Caco-2 junctional complex, thus reducing TJ integrity and decreasing 
intestinal epithelial resistance (Dorkoosh et al., 2004; Yeh et al., 2011). 
Low molecular weight chitosan has a molecular weight of 50 - 190 kDa which prevents it 
from crossing the epithelium even after opening of the paracellular path. Several derivatives 
have been developed. The most recent are chitosan nanoparticles, which interact directly with 
the cell membrane via endocytosis and transcytosis and enhance the transport of drug 
molecules through the blood-brain barrier or the intestinal barrier (Lalatsa et al., 2012a, 
2012b; Sandri et al., 2010; Vllasaliu et al., 2010). Thus, this new generation of enhancer is 
able to modulate transcellular transport in addition to the paracellular pathway.  
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4.4 Peripheral opioid receptor agonists 
AS006 (Fig. 6 A) is a morphinan derivative which selectively activates µ-opioid receptors. Its 
structure is similar to the morphine molecule (Fig. 6 B) and is the equivalent to 2-(4,5α-
epoxy-3-hydroxy-14β-methoxy-17-methyl-morphinan-6β-yl)aminoacetic acid (HS-731). It is 
a zwitterionic molecule with increased hydrophilicity (log P = 0.27) and a molecular weight 
of 374.4 Da. The hydrophilicity is enhanced by the presence of an amino acid residue 
(glycine) at C-6 of the morphinan. This restricts the opioid from crossing the blood–brain 
barrier (Schütz et al., 2003). Bileviciute-Ljungar and colleagues have shown that 
subcutaneous (s.c.) administration of AS006 reduces nociceptive responses as manifested by 
increased paw withdrawal latencies to mechanical and thermal stimulation in a rat model of 
inflammatory pain. Oral administration of AS006 significantly reduced hyperalgesia (“pain 
sensitivity”) in inflamed paws. This effect was reversible by naloxone methiodide (NLXM), 
an opioid receptor antagonist that does not cross the blood-brain barrier (Bileviciute-Ljungar 
et al., 2006). In a mouse model of visceral pain preemptive s.c. administration of AS006 
produced potent peripherally mediated antinociception (Al-Khrasani et al., 2007). In 
summary, AS006 has demonstrated analgesic efficacy in several models for acute and chronic 
inflammatory pain (Bileviciute-Ljungar et al., 2006; Al-Khrasani et al., 2007).  
Loperamide, another selective µ-opioid receptor agonist, is a synthetic piperidine derivative 
with a molecular weight of 477.0 Da (Fig. 6 C). Previous studies have shown that 
intravenously (i.v.) injected loperamide cannot cross the blood-brain barrier because it is a 
substrate of P-gp (Mercer and Coop, 2011; Schinkel et al., 1996a). Others have demonstrated 
that the high lipophilicity of loperamide (log P = 4.26) is underlying its high affinity to P-gp 
(Wiese and Pajeva, 2001). Studies in humans have shown that inhibition of P-gp with 
quinidine leads to an increased entry of loperamide into the CNS with resultant respiratory 
depression (Sadeque et al., 2000). Several experimental studies have shown that loperamide is 
an effective peripherally acting analgesic administered by mouth wash (in humans) (Nozaki-
Taguchi et al., 2008), i.v. (in rats), intraperitoneal (i.p.) (in rats and mice), and intraplantar 
(i.pl.) injection in different pain models (inflammatory, muscular, neuropathic, cancer, and 
visceral pain) (DeHaven-Hudkins et al., 1999; Guan et al., 2008; Nozaki-Taguchi and Yaksh, 
1999; Sánchez et al., 2010; Sevostianova et al., 2005; Shannon and Lutz, 2002; Shinoda et al., 
2007). Clinically, loperamide is currently used to control diarrhea (Baselt, 2004; Niemegeers 
et al., 1981; Tseong, 1995). In the gastrointestinal tract, μ-opioid receptors are expressed by 
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myenteric and submucosal neurons, and on immune cells in the lamina propria (Tonini et al., 
1992). Loperamide can inhibit acetylcholine release from myenteric motor neurons to 
attenuate twitch contractions of longitudinal muscles in response to transmural electrical 
stimulation (Dingledine and Goldstein, 1976). Since P-gp is located on the apical membrane 
of intestinal epithelial cells and is able to pump loperamide back into the intestinal lumen, 
only low amounts of loperamide can enter the blood circulation when administered orally 
(Silverman, 1999; Thiebaut et al., 1987a). Due to its low absorbance from the intestinal tract, 
loperamide is viewed as a compound with a low oral bioavailability with no side effects on 
the CNS (Baselt, 2004). Taken together, loperamide represents a peripheral opioid receptor 
agonist that is readily available and already in clinical use. Therefore, we decided to initially 
focus our in vivo studies on this compound.  
 
 
 
 
 
 
 
 
Figure 6: Chemical structures of AS006 (A), morphine (B) and loperamide (C)  
B A C 
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5 OBJECTIVES 
The aim of this study was to investigate the intestinal transport of peripherally acting opioids 
(AS006, loperamide) and their antinociceptive properties after oral administration. To 
increase intestinal absorption, chitosan was used.  
Hypothesis 1: The intestinal permeability for AS006 is low. To test this hypothesis, a 
detection method for the quantification of AS006 using liquid chromatography coupled with 
tandem mass spectrometry (LC-MS/MS) had to be developed and validated for the specific in 
vitro conditions applied here. Ussing chamber experiments were performed to analyze the 
amount of AS006 passing human intestinal colon cell monolayers. 
Hypothesis 2: The intestinal permeability for loperamide is low. To test this hypothesis, a 
detection method for the quantification of loperamide using LC-MS/MS had to be developed 
and validated for the specific in vitro conditions applied here. Ussing chamber experiments 
were performed to analyze the loperamide passage across human intestinal colon cell 
monolayers. 
Hypothesis 3: Chitosan increases permeability of AS006 across intestinal epithelia. To test 
this hypothesis, in vitro Ussing chamber experiments were performed to analyze the 
transepithelial flux of AS006 across human intestinal colon cell monolayers in the presence of 
chitosan. AS006 was quantified using LC-MS/MS. 
Hypothesis 4: Chitosan increases the permeability of loperamide across intestinal epithelia. 
To test this hypothesis, in vitro Ussing chamber experiments were performed to analyze 
loperamide flux across human intestinal colon cell monolayers in the presence of chitosan. 
Loperamide was quantified using LC-MS/MS. 
Hypothesis 5: Chitosan improves the antinociceptive effect of orally administered loperamide 
in rats with hindpaw inflammation in vivo. To test this hypothesis, paw pressure thresholds 
were assessed in rats receiving oral combinations of loperamide with/without chitosan.  
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6 MATERIALS AND METHODS 
6.1 Materials 
6.1.1 Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) 
Auto sampler SIL-HTA     Shimadzu, Duisburg, Germany 
Column thermostat CTO-20A    Shimadzu, Duisburg, Germany 
Degasser 2 DGU 20 A Shimadzu, Duisburg, Germany 
HPLC  Shimadzu, Duisburg, Germany 
Pumps 2 LC-20AD Shimadzu, Duisburg, Germany  
Switching valves 2 FCV-14 AH Shimadzu, Duisburg, Germany 
Triple-Quadrupol-Massenspektrometer QTrap 3200 AB SCIEX, Darmstadt, Germany 
6.1.2 Ussing chamber system 
Ohmmeter Institut für Klinische Physiologie, 
Charité Universitätsmedizin 
Berlin, Germany 
Ussing-chamber Institut für Klinische Physiologie, 
Charité Universitätsmedizin 
Berlin, Germany 
6.1.3 Behavioral experiments 
Alsident® system 25 - Cabinet type 1 Alsident System A, Hammel, 
Denmark 
Analgesy-Meter Ugo Basile, Comerio, Italy 
Feeding needle (metal, gauge 15, length 78 mm, ball OD 2.9 mm) AgnTho's AB Lidingö, Sweden 
Glass exsiccator DURAN Group GmbH, 
Wertheim/Main, Germany 
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6.1.4 General appliances 
Analytical scale XS 105 with printer RS-P42 Mettler-Toledo, Gießen, Germany 
CO2 incubator CB-150      Binder, Tuttlingen, Germany 
Microliter syringes Hamilton, Bonaduz, Switzerland 
Pipettes Eppendorf, Köln, Germany 
sterile bench Gelaire Flow Laboratories, 
Meckenheim, Germany 
Vortex-Genie 2 Scientifica Industries, Inc., New 
York, USA 
6.1.5 LC-MS/MS  
Atlantis dC18 column, 2.1 mm x 20 mm, 3 µm Waters GmbH, Eschborn, 
Germany 
C18 guard column 4 x 3.0 mm  Phenomenex Aschaffenburg, 
Germany 
Luna PFP column, 150 mm × 3.0 mm, 3 μm       Phenomenex Aschaffenburg, 
        Germany 
Luna PFP guard column 4 x 3.0 mm  Phenomenex Aschaffenburg, 
Germany 
Autosampler vials, 2 mL, 12 x 32 mm  Laubscher Labs, Miecourt, 
Switzerland 
screw cap for autosampler vials CS-Chromatographie Service 
Langerwehe, Germany 
Vial inserts, 200 μL, glass  Kunz & Müller Berlin, Germany 
6.1.6 Cell culture  
Cell scrapers       Coster, Corning, NY, USA 
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Dishes        Nunc, Karlsruhe, Germany 
Flasks        Nunc, Karlsruhe, Germany 
Membrane filter, 0.22 μm, Polyvinyl-denfluorid   Millipore Eschborn, Germany 
Tips        Eppendorf, Köln, Germany 
Transwell filter, Millicell-HA, Millicell- PCF, 0.6 cm² Millipore, Schwalbach, Germany 
Tubes        Eppendorf, Köln, Germany 
 
6.1.7 Behavioral experiments 
BD Microlance 3TM (26 Gx1/2, 0.45mm x 13mm) Becton Dickinson GmbH 
Heidelberg, Germany 
BD Microlance 3TM (30 Gx1/2, 0.3 mm x 13mm) Becton Dickinson GmbH 
Heidelberg, Germany 
BD Plastipak 1 mL Becton Dickinson GmbH 
Heidelberg, Germany 
Health care respirator, FFP3  3M, St. Paul, MN, USA 
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6.1.8 Chemicals      
Acetic acid, 96%  Merck, Darmstadt, Germany 
Acetonitrile, Optigrade  LGC Standards, Wesel, Germany  
Acetylcysteine Hexal, Barleben, Germany 
Ammonium acetate p.a. Merck, Darmstadt, Germany 
AS006        AlcaSynn GmbH, Austria 
Chitosan with low molecular weight Sigma-Aldrich, Steinheim, 
(50 - 190 kDa based on viscosity), 75 - 85% deacetylation Germany 
Freund’s Complete Adjuvant,  Merck KGaA, Darmstadt,  
(10 mL homogenized in the following proportions by weight:  Germany 
85% Drakeol 5NF, 15% Aracel A (mannide monooleate emulsifier),  
0.1% Mycobacterium butyricum dry cells)  
ddH2O membraPure, Bodenheim, 
Germany 
Dimeticon 350-siliciumdioxid 92,5 : 7,5  Sab Simplex, Pfizer GmbH, 
Berlin, Germany 
DMSO Sigma-Aldrich, Steinheim, 
Germany 
Fetal bovine serum (FBS)  PAA Laboratories GmbH, 
Pasching, Austria 
Formic acid (>98%) Fluka, Buchs, Switzerland  
Glucose Sigma-Aldrich, Steinheim, 
Germany 
D-(+)-glucose monohydrate Sigma-Aldrich, Steinheim, 
Germany 
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L-Glutamine Sigma-Aldrich, Steinheim, 
Germany 
HEPES Serva, Heidelberg, Germany 
Histoacryl® tissue glue  Aesculap AG, Tuttlingen, 
Germany 
3-Hydroxybutyric acid Sigma-Aldrich, Steinheim, 
Germany 
Isoflurane Abbott, Wiesbaden-Delkenheim, 
Germany 
Loperamide hydrochloride Sigma-Aldrich, Steinheim, 
Germany 
Magnesium chloride       Merck, Berlin, Germany 
D-(+)-mannose Sigma-Aldrich, Steinheim, 
Germany 
Methadone-d3, 100 ug/mL Cerilliant Corporation, Texas, 
USA 
Methanol, LC-MS Chromasolv  Fluka, Buchs, Switzerland 
Minimum Essential Medium (MEM) + GlutaMAXTM  Gibco®, Karlsruhe, Germany 
Morphine-d3, 1.0 mg/mL Cerilliant Corporation, Texas, 
USA 
Morphine sulfate salt pentahydrate (758.83 MW) Sigma-Aldrich, Steinheim, 
Germany 
Natrium chloride  Serva, Heidelberg, Germany 
Penicillin PAA Laboratories GmbH, 
Pasching, Austria 
Piperacillin        Hexal, Barleben, Germany 
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RPMI 1640-Medium  PAA, Pasching, Austria 
Sab Simplex  Pfizer GmbH, Berlin, Germany 
Streptomycin  PAA Laboratories GmbH, 
Pasching, Austria 
Trypsin-EDTA Sigma-Aldrich, Steinheim, 
Germany 
Zienam Msd Sharp & Dohme GmbH, 
Haar, Germany 
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6.1.9 Solutions  
HEPES-buffered Ringer's solution: 
140 mM NaCl, 5.4 mM KCl, 1 mM MgSO4, 1.2 mM, CaCl2, 10 mM HEPES, 10 mM glucose, 
adjusted to pH 7.4 with NaOH (1M) 
Substrate solution for rat duodenum experiments: 
3-Hydroxybutyric acid 1.26 g, L-glutamine 7.3 g, D-(+)-mannose 36.04 g, D-(+)-glucose 
monohydrate 39.6 g, piperacillin 1.0 g, Zienam 0.2 g for 20 L HEPES 
6.1.10 Software 
ACD/ChemSketch (freeware version) Advanced Chemistry Development 
(ACD/Labs), Frankfurt, Germany 
Adobe Photoshop CS5 Extended Adobe Systems Inc., San Jose, 
California, USA 
Analyst™ software version 1.5.1    AB SCIEX, Darmstadt, Germany 
B.E.N. version 2.03      ARVECON GmbH, Walldorf, 
        Germany 
Software program Analogon D. Sorgenfrei, Institut für 
Klinische Physiologie, Charité 
Univeritätsmedizin Berlin, Berlin, 
Germany 
Statistics program GraphPad Prism 5 GraphPad Software Inc., San 
Diego, California, USA 
VALISTAT version 2.0 ARVECON GmbH, Walldorf, 
Germany 
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6.2 Methods 
6.2.1 Liquid chromatography coupled with tandem mass spectrometry  
The LC-MS/MS technique combines high performance liquid chromatography (HPLC) with 
tandem mass spectrometry (MS/MS). For data recording and analysis the Analyst ™ software 
(version 1.5.1; AB SCIEX, Darmstadt, Germany) was used. 
6.2.1.1 High performance liquid chromatography  
HPLC is an analytical method to separate, identify and quantify substances in solution. The 
mobile phase containing the analyte of interest is injected through a pump into a column made 
of specific chromatographic packing material (the stationary phase). The analyte interacts 
with the stationary phase according to its physicochemical properties resulting in a specific 
retention time for each analyte.  
The HPLC system consisted of two DGU 20-A degassers, two LC-20AD pumps, one 
optionBox and two FCV-14 AH switching valves, a CTO-20A column thermostat and an SIL-
HTA auto sampler (all from Shimadzu, Duisburg, Germany). The liquid chromatograph was 
coupled to a triple quadrupole mass spectrometer (3200 QTRAP®; AB SCIEX, Darmstadt, 
Germany). The mobile phase was consisted of: 
Eluent A: MeOH/H2O (97/3, v/v) + 10 mM ammonium acetate + 0.1% acetic acid 
Eluent B: MeOH/H2O (10/90, v/v) + 5 mM ammonium acetate + 0.1% formic acid 
Eluents were filtered through a Millipore filter (0.22 μm) before being used. 
6.2.1.2 Mass spectrometry  
Mass spectrometry (MS) is an analytical method to measure the molecular weight (MW) of 
atoms, molecules and molecule fragments. Mass spectrometry measures the mass-to-charge 
ratio (m/z) of ionized particles spraying in droplets from the needle with a surface charge of 
the same polarity as the charge of the needle. This ion source is named electro spray 
ionization (ESI). Because of the equal charges the droplets are repelled from the needle and 
directed towards the source sampling cone on the counter electrode. As the droplets cross the 
space between the needle tip and the orifice, the surface tension can no longer sustain the 
charge (the Rayleigh limit) at which point a “Coulombic explosion” occurs and the droplets 
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are dispersed. The molecules of the sample are charged in single or multiple ways (Griffiths et 
al., 2001). Once the molecules are ionized in the gas phase, their m/z ratio is determined 
(Griffiths and Wang, 2009).  
The ESI ion source is combined with a quadrupole analyzer, with a continuous ion flow. The 
quadrupole works as a mass filter and consist of four parall metal rods with identical 
interspaces. The metal rods have an alternate current (ac) voltage and a direct current (dc) 
voltage, the diagonal partners have the same ac and dc voltage while the other pair is 
oppositely charged. Only ions with a specific m/z pass all the way through the quadrupole 
with a specific ac/dc (Chernushevich et al., 2001, Wade, 2002). 
A MS/MS was used to provide improved sensitivity and selectivity. Therefore, three 
quadrupoles were connected in series. The first analyzer isolates the precursor ion, (Q1), the 
next step is the fragmentation of the ion in the second quadrupole, (Q2). The last analyzer 
separates the fragments according to their m/z ratio (Q3) (see Fig. 7). The detection occurs via 
a continuous-dynode electron multiplier. Ions impact on the lead-coated surface of a glass 
capillary followed by a release of electrons. The resulting cascade increases the amount of 
electrons which is amplifying the signal intensity (Pavia and Lampman, 2009).  
The triple quadrupole mass spectrometer with a turbo electrospray ion source (EIS) used here 
operated in the positive ionization mode (ESI+). The source temperature was 450 °C and the 
ion source voltage was set to 4500 V. For the analytes (AS006, loperamide) two mass 
transitions (quantifier and qualifier) were chosen. For each internal standard (IS) a single 
mass transition was used. Compounds were quantified in the multiple reaction mode (MRM), 
which allows a screening of several target ions (Kitteringham et al., 2009). 
To reduce contamination of the MS system by highly concentrated salts of experimental 
buffer solution, a switching valve on board 3200 QTRAP® was used, which opened 1.7 min 
before the initial peak and closed after 3.6 min for the detection of AS006. For loperamide, 
the valve opened 0.8 min before the initial peak and closed after 2.3 min.  
 
 
 
Figure 7: The QTrap 3200 mass spectrometer (modified after Applied Biosystems, 2005.)  
 
ESI Ion Source 
Ion Flow  
High Pressure 
Cell Precursor Ion Fragmentation m/z Separation Detection 
Q1 Q2 Q3 
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6.2.2 Columns 
6.2.2.1 Pentafluorophenyl column 
For the chromatographic separation of the hydrophilic AS006 (log P = 0.27) a Phenomenex 
pentafluorophenyl (PFP) column (150 mm × 3. 0 mm, 3 μm particle size) and a Luna PFP 4 x 
3 mm guard column was used. This stationary phase is specifically designed for polar 
compounds and applies a unique dipole retention mechanism to improve selectivity especially 
for polar analytes. The analytical column contains silica gel functionalized with PFP-groups. 
Analyte compounds are separated due to π-π-interactions, dipole-dipole interactions as well as 
hydrogen bonds.  
The following gradient was used for elution: 0 - 3 min: 95 - 6% B (linear), 3 - 3.5 min: 6% B, 
3.5 - 5.0 min: 5 - 95% B (linear). The flow rate was 0.5 mL/min, and the total run time was 
5 min.  
6.2.2.2 Atlantis dC18 Column 
For the LC-MS/MS analyzes of the hydrophobic loperamide (log P = 4.26) the Atlantis dC18 
Column (2.1 mm x 20 mm, 3 µm particle size) was used. C18 columns are highly 
hydrophobic and used for reversed phase liquid chromatography.  
To prevent rapid deterioration of the analytical column, a Phenomenex C18 guard column 4 x 
3.0 mm was used.  
The following gradient was used for elution: 0 - 1.5 min: 95 - 5% B (linear), 1.5 - 2.5 min: 5% 
B, 2.5 - 3.0 min: 5 - 95% B (linear). The flow rate was 0.7 mL/min, and the total run time was 
3 min.  
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6.2.3 Validation 
The validation of analytical methods is a prerequisite for the quality and comparability of 
results. The validations of these two methods were performed following the guidelines 
published by Peters et al. (Peters et al., 2007) and the guidelines of the Society of 
Toxicological and Forensic Chemistry (GTFCh) (Peters et al., 2009) to fulfill quality 
requirements for routine analysis of pharmacologically active substances applied in humans. 
The validation focused on homogeneity of calibrators, homogeneity of controls, specificity, 
selectivity, ion suppression, definition of measurement range, calibration, lower limit of 
quantification, and verification of accuracy of measurement. It is a widely performed standard 
validation procedure employed at the Institute Labor Berlin, Department of Clinical 
Toxicology and Pharmacology (Köhler et al., 2011) and other clinical toxicology laboratories 
for novel methods of drug detection. The suitability of each procedure must be demonstrated 
and documented before sample testing (Peters et al., 2007).  
6.2.3.1 Precision and bias 
The bias is calculated as a reference for the difference between the actual and a desired value 
and serves as a tool for the accuracy of quantitative analysis methods: 
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6.2.4 Validation of LC-MS/MS method for AS006 
6.2.4.1 Determination of quantifier and qualifier ion fragments 
Two fragments of the analyte were monitored. The fragment yielding the most intense signal 
was used as the quantifier ion, the less intense fragment served as qualifier ion. Each of them 
has a specific mass transition as analyzed by MS/MS.  
6.2.4.2 Sample preparation protocol for measurements of AS006 
50 µL internal standard morphine-d3 (100 ng/mL) were added to 100 µL of each sample, 
mixed and then measured with an injection volume of 10 µL. Samples with an AS006 
concentration higher than 100 ng/mL were diluted 1:1000 in HEPES-buffered Ringer`s 
solution to fit the linear range of the standard curve. This way of sample preparation should 
reveal a standard curve with linear regression coefficients ≥ 0.999. All results are related to 
the mass transition of the quantifier ion. 
6.2.4.3 Quantification of AS006  
To determine the analyte concentration, samples with defined amounts of analyte (calibrators, 
1, 4, 8, 25, 40, and 100 ng/mL) in HEPES-buffered Ringer's solution were used to create an 
AS006 standard curve. The standard curve usually showed a linear regression coefficient 
close to 1 (≥ 0.999). In addition, three quality control samples (QC I, QC II, QCL III: 7.5, 40, 
and 75 ng/mL) were used. For quantification, the relative peak area of the analyte was 
compared to the peak area of the IS. Sample peaks were automatically integrated and 
concentrations in unknown samples were calculated from the resulting calibration curves.  
The linearity of the calibration was tested using the software "B.E.N."(version 2.03, Arvecom, 
Walldorf, Germany). This program plots the relative peak area (y-axis) against the calibrator 
concentration (x-axis) and the characteristics of the calibration are automatically calculated. 
The following settings were used: 
Significance level:  99% (homogeneity of variance)  
Uncertainty of results: 3 /33% (K-value / percent value) 
Number of measurements: 1 
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Outlier test (F-test): 
First, outliers were identified using the outlier test (F-test). If an outlier (significance 
level 99%) was found, it was excluded and the test was repeated. When the highest calibrator 
had to be excluded, the linear range was adjusted accordingly.  
Linearity of the calibration (F-test for linearity, Mandel test): A 1st order calibration was 
always performed. 
6.2.4.4 Homogeneity of calibrators  
Calibrator C (8.00 ng/mL AS006) of the in-house pool was considered representative of all 
other calibrators. The calibrator was analyzed six times following the analytical procedure 
described above, to check its homogeneity.  
The relative peak area (Q values) was calculated according to the following equation: 
)(
)(
ISAREA
AnalytAREAQ =
 
Here, outliers were found and eliminated using the Grubbs test (Microsoft Office Excel). At 
least five values should remain to provide evidence on the calibrator`s homogeneousness. The 
relative standard deviation (RSD) should be ≤ 20%. 
6.2.4.5 Homogeneity of controls  
The controls (QC I and QC III) were analyzed six times according to the analysing protocol to 
check their homogeneities. 
Outliers were identified and eliminated using the Grubbs test (Microsoft Office Excel). At 
least five values are needed to ascertain the homogeneousness of the calibrators. 
The RSD should be lower than ≤ 20%. 
6.2.4.6 Specificity  
The specificity test verifies the identity of the analyte and reflects interferences caused by 
other compounds contained in the sample. Therefore, individual solutions of the substances 
(including IS) with a concentration of 1 µg/mL in mobile phase B (s.a.) were prepared 
(100 μL standard solution (β = 0.01 mg/mL) + 900 μL mobile phase B) and analyzed.  
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6.2.4.7 Selectivity 
The selectivity test shows that the analyte can be clearly identified without disturbance of 
other potentially contaminating substances (e.g. metabolites, impurities, and matrix).  
Selectivity was tested in a mixture of 100 µL HEPES buffered Ringer`s solution and 50 µL IS 
morphine-d3 (100 ng/mL); the injection volume was 10 µL. 
6.2.4.8 Selectivity test for chitosan 
1. 1 mL HEPES (+ 5 µL ddH2O)  
2. 1 mL HEPES (+ 5 µL Chitosan 1% solution)  
100 µL of each solution were mixed with 50 µL internal standard morphine-d3 (100 ng/mL). 
The injection volume was 10 µL.  
6.2.4.9 Ion suppression test (peak area evaluation) 
Co-elution of analytes and matrix components can significantly reduce or enhance the 
ionization of the analyte. Due to low and/or fluctuating signal intensity quantification can get 
impossible. To exclude a possible ion suppression/enhancement, the analyte was dissolved 
and analyzed in eluent B (reconstitution solution, RCS) and in processed blank solution 
(without IS) (spiked blank sample) as follows: 
First, the stock solution of the analyte AS006 (0.1 mg/mL) was diluted 1:100 in MeOH. Then 
40 µL of this dilution were dried to remove the MeOH and redissolved in 1 mL HEPES + 
0.5 mL ddH2O. 
The analyte peak areas of the spike blank sample were compared to those of the RCS sample. 
A peak area reduction/increase exceeding 15% was considered to be ion 
suppression/enhancement. 
%100
solvent pure Area
blank spiked Area -solvent pure Areareduction  areaPeak ×





=  
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6.2.4.10 Ion suppression test for chitosan 
First, the stock solution of the analyte AS006 (0.1 mg/mL) was 1:100 diluted in MeOH.  
Afterwards 40 µL were evaporated and redissolved in 1 mL HEPES + 0.5 mL ddH2O and in 
1 mL HEPES + Chitosan 7.5µL (0.00025%) + 0.5 mL ddH2O. 
The analyte peak areas of the spiked blank sample were compared to those of the RCS. The 
peak area reduction < -15% was considered as ion suppression.  
6.2.4.11 Lower limit of quantification 
The calibrator with the lowest analyte concentration (A = 1 ng/mL) was diluted 1:2 and 1:5 in 
HEPES Ringer`s solution to determine the lower limit of quantification (LLOQ) of the 
method. The measurement was repeated six times and samples were prepared according to the 
analysing protocol (see paragraph 6.7.4.2).  
6.2.4.12 Definition of measurement range 
The range of calibrators corresponds to the concentration range of the analyte in the sample, 
which allows a quantitative determination of the analyte with defined accuracy. The lower 
limit corresponds to the LLOQ. The upper limit is the upper limit of linear range (see 
paragraph 6.7.4.3 on calibration). 
6.2.4.13 Verification of accuracy of measurement 
On eight consecutive days calibrators and control samples were analyzed following the 
procedure detailed above. 
For testing the linearity of the calibration the software "B.E.N." was used. The program plots 
the relative peak area (y-axis) against the calibrator concentration (x-axis) and the 
characteristics of the calibration are automatically calculated. 
The following settings were used: 
Significance level:  99% (variant homogeneity)  
Uncertainty of results: 3 / 33% (K-value / percent-value) 
Number of measurements: 8 
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Outlier test (F-test): 
Outliers were identified using the F-test. If an outlier (significance level 99%) was found, it 
was excluded and the test was repeated. When the highest calibrator had to be excluded, the 
linear range was adjusted accordingly.  
Linearity of the calibration (F-test for linearity, Mandel test): A 1st order calibration was 
always performed. 
 
6.2.5 Validation of LC-MS/MS method for loperamide 
6.2.5.1 Sample preparation protocol 
A volume of 50 µL IS methadone-D3 (50 ng/mL solved in acetonitrile) was added to 100 µL 
of the sample, briefly vortexed and centrifuged for 5 min at 20,000 x g. Subsequently, 100 µL 
were carefully transferred into a glass vial and measured with an injection volume of 25 µL. 
Samples with a concentration higher than 100 ng/mL were diluted in HEPES-buffered 
Ringer's solution to fit the linear range of the standard curve. This revealed a standard curve 
with linear regression coefficients > 0.995. All results are related to the mass transition of the 
quantifier ion. 
6.2.5.2 Quantification of loperamide in HEPES-buffered Ringer`s solution 
Samples with defined amounts of analyte (calibrators) were used to create a loperamide 
standard curve in HEPES-buffered Ringer's solution. A linear standard curve based on six 
different calibrators (1, 5, 10, 25, 50 and 100 ng/mL) and two QC samples (QC I: 7.5 and QC 
II: 75 ng/mL) was used. For quantification, the relative peak area of the analyte loperamide 
was compared to the peak area of the IS. Sample peaks were automatically integrated and 
concentrations in unknown samples were calculated from the resulting calibration curves 
(Analyst™ software, version 1.5.1, AB Sciex, Darmstadt, Germany).  
The linearity of the calibration was tested using the VALISTAT- software for method 
validation in forensic toxicology (version 2.0, ARVECON GmbH, Germany, Walldorf). This 
program plots the relative peak area (y-axis) against the calibrator concentration (x-axis) and 
the characteristics of the calibration are automatically calculated.  
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The following settings were used: 
Significance level:  99% (homogeneity of variance)  
Uncertainty of results: 3 /33% (K-value / percent value) 
Number of measurements: 1 
Outlier test (F-test): as described above (6.2.4.13) 
6.2.5.3 Specificity 
Solutions of the substances (including IS) with a concentration of 1 µg/mL in the mobile 
phase B were prepared (100 μl standard solution β = 0.01 mg/mL + 900 μl mobile phase B) 
and analyzed. Two solutions, one with loperamide and one with the IS methadone-D3 were 
measured.  
6.2.5.4 Selectivity 
The analyte should be clearly identifiable without any disturbances of other potentially 
contaminating substances (e.g. metabolites, impurities, and matrix) in the HEPES-buffered 
Ringer's solution. Therefore, HEPES solutions without IS were measured twice and the 
chromatogram was analyzed. 
6.2.5.5 Precision and accuracy 
Inter-day precision and accuracy were determined by analysing eight QC samples from both 
concentrations on eight consecutive days. Both sample levels were processed and analyzed. 
Intra-day precision and accuracy were determined by analysing eight QC samples of both 
concentrations on the same day. The measured concentrations were tested for outliers using 
the Grubbs test. Outliers were eliminated when criteria fulfilled recommendations for relative 
standard deviation, and bias values.  
6.2.5.6 Limits of quantification 
The lower limit of quantification (LLOQ) was the lowest concentration yielding a relative 
standard deviation and bias ≤ 20%. The calibrator with the lowest analyte concentration 
(A = 1 ng/mL) was diluted 1:2, 1:5 and 1:10 in HEPES Ringer's solution to determine the 
LLOQ. The measurement was repeated 8 times and samples were prepared according to the 
protocol for analysis. The upper limit of quantification (ULOQ) was assumed to be equal to 
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the upper limit of the linear range. To determine the ULOQ a complete series of calibrators 
was analyzed on 8 consecutive days. 
6.2.5.7 Matrix effect  
A possible effect of coeluting matrix compounds on the ionization of the analyte was 
investigated by post-column infusion of a standard solution containing loperamide (10 µg/mL 
in eluent B) and methadone-D3 (10 µg/mL in eluent B) via a syringe pump (Harvard 
Apparatus, Holliston, MA, USA) with a flow rate of 10 µL/min while simultaneously 
analysing a blank HEPES-buffered Ringer's solution sample.  
6.2.5.8 Stability 
To investigate freeze/thaw stability, six samples from each QC (QC I: 7.5 ng/mL and QC II: 
75 ng/mL) were subjected to three freeze/thaw cycles, each consisting of a 20 h freezing 
phase and a 20 h thawing phase. Concentrations of these pretreated samples were compared to 
untreated samples (n = 6). The mean of the pretreated samples had to be within a ±10% 
interval of the mean of the untreated samples, while the 90% confidence interval was 
supposed to be within a ±20% interval of the mean of untreated samples.  
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6.2.6 Epithelial cell culture 
Two different colon epithelial cell lines were used. To avoid contamination of the growing 
cell culture, cells were trypsinated in the presence of EDTA three times for 5 min at 37°C and 
5% CO2. Trypsin helps to detach the cells from the flask surface and EDTA binds Ca2+ ions 
and destabilizes membrane proteins which lead to relaxation of cell structures. To avoid 
deactivation of trypsin the flask was washed before trypsination with Ca2+ and Mg2+ free PBS 
(Boxberger, 2006). For each cell filter (0.6 cm2) 500 µL of the cell suspension was seeded, 
which corresponded to approximately 450,000 cells.  
6.2.6.1 Caco-2 cell line 
The Caco-2 cell is a well-characterized, human colon adenocarcinoma cell line. It is used for 
high-throughput screening of drug permeability. Caco-2 cells form a confluent epithelial cell 
monolayer consisting of columnar and polarized cells that expresses microvilli on the apical 
membrane and forms TJs between adjacent cells (Hidalgo et al., 1989). Caco-2 cells express 
various transporters, enzymes, and nuclear receptors (Sun et al., 2008).  
Caco-2 cells were grown near confluence in monolayer cultures on permeable Millicell HA 
filters (pore size 0.45µm) at 37°C in an atmosphere of 5% CO2 in Minimum Essential 
Medium (MEM) + GlutaMAXTM containing 15% (v/v) fetal bovine serum (FBS) and 1% 
penicillin/streptomycin. Cell filters with 0.6 cm2 surface (~ 450,000 cells) were used for the 
Ussing chamber experiments 14 days after cell monolayers had reached a polarized 
confluence, giving a TER of ~ 300 Ω·cm².  
6.2.6.2 HT29/B6 cell line 
The HT29/B6 cell line consists of human colonic adenocarcinoma cells which form polarized 
and confluent growing monolayers (Kreusel et al., 1991). They have chloride-secreting and 
mucus producing properties (Hayslett et al., 1987). HT29/B6 were cultivated in RPMI 1640 
with 10% FBS and 1% Penicillin/Streptomycin and grown on permeable Millicell PCF filters 
(pore size 3 µm). After 7 - 8 days, the cell monolayer filters were mounted in Ussing 
chambers filled with HEPES-buffered Ringer's solution. The TER of HT29/B6 was                    
~ 500 Ohm*cm² which indicated a tight epithelial cell model. 
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6.2.7 Ussing chamber technique  
This in vitro method is used to analyze the electrical resistance of cell monolayers or native 
tissues as well as transport mechanisms for ions and macromolecules (Sun et al., 2008). TER 
is calculated from voltage changes (ΔV) induced by short current pulses (50 mA, 0.3 s). The 
electrical circuitry is used to determine resistance (R), current (I) and voltage (V), as well as 
impedance and capacitance (Kreusel et al., 1991). The Ussing chamber (Fig. 8 and 9) consists 
of a U-shaped tube two chamber system, which separates the basolateral and the apical side of 
a cell monolayer grown on a permeable support. Both chamber sides were filled with 5 mL 
HEPES-buffered Ringer's solution at a pH of 7.4 and heated up to 37°C. To ensure good 
circulation and oxygenation of the solution, both chamber sides were permanently gassed with 
a mixture of 95% O2 and 5% CO2. The compound of interest (AS006, loperamide, chitosan) 
was added to the apical side, respecticely. Samples from both sides were taken at defined time 
intervals.  
 
 
 
 
 
 
 
 
 
Figure 8: Ussing chamber setup (modified after Li et al., 2004).  
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Figure 9: Typical Ussing chamber system.  
The Ussing chamber system was checked for noise and offset voltages prior to the 
experiments. Subsequently, the resistance of the empty chambers, a parameter required for 
correct calculation of resistance and currents, was determined (Kreusel et al., 1991). For 
controlling and timing of measurements the software program Analogon (Ing. grad. D. 
Sorgenfrei) was used.  
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6.2.8 Transepithelial resistance   
Transepithelial resistance was recorded as an indicator for barrier properties of the epithelial 
cell monolayers grown on permeable supports. The major structural correlate of barrier 
properties is the tight junction, which determines polarity and paracellular permeability, and 
therefore integrity of the epithelial tissue (Kreusel et al., 1991). A decrease in electrical 
resistance can reflect a decrease in tightness of TJs, and therefore an increased paracellular 
permeability for solutes.  
Using the current (I) and the potential difference (U) the electrical resistance (Rt) is calculated 
using Ohm`s law:  






∆
∆
=
I
UR  
6.2.9 Ussing chamber experiments with cell monolayers 
After inserting the cell culture filter, both chamber sides were filled with 5 mL HEPES-
buffered Ringer's solution, and TER was measured. After reaching a stable baseline, the 
transepithelial voltage was clamped to 0 mV. Loperamide was first solved in ≥ 99.7% DMSO 
and then further diluted in HEPES-buffered Ringer's stock solution to a final concentration of 
10 µM. AS006 was used at a final concentration of 27.2 µM (10.2 µg/mL) dissolved in 
ddH2O. Chitosan and the vehicle control were added at the same volume (25 µL) to the apical 
side. First, the substance of interest (AS006 or loperamide) was added to the apical side. After 
5 min samples were taken from both chamber sides, representing the time point zero. Each 
time an equal volume of fresh HEPES-buffered Ringer's solution was replaced. Subsequently, 
chitosan was added to the apical side. Samples were then taken at defined intervals and stored 
at -80°C until they were analyzed by LC-MS/MS. 
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6.2.10 Permeability 
The permeability describes the rate of drug transport into the receiver compartment 
(basolateral side) depending on the drug concentration on the apical side and the area of the 
cell filter membrane (Hernández-Covarrubias et al., 2012; Kataoka et al., 2011; Yamashita et 
al., 2002).  
The following equation was used to determine the permeability P: 
[ ]sec/cmAREAfilter
Co
tM
P





 ∆∆
=  
Δ M/ Δ t rate of drug transport into receiver compartment in ng/sec 
Δ M  amount of drug on the basolateral side in ng   
Δ t  time interval in sec 
Co   concentration of drug added to the apical side in ng/mL 
AREAfilter area of the filter membrane in cm² 
Substances with permeability values of P > 10 × 10-6 cm/s, between 0.3 × 10-6 and                 
10 × 10-6 cm/s, < 0.3 × 10-6 cm/s are termed to be highly, moderate, and poorly permeable 
compounds, respectively (Fichert et al., 2003). 
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6.2.11 Ussing chamber experiments with rat duodenum  
Male Wistar rats (250 - 300 g) (from Harlan Laboratories, Netherlands) were kept on a 
constant light-dark cycle with free access to tap water and food in temperature-regulated 
(23°C) animal rooms. Rats were killed by CO2 overdosing and the duodenum was removed 
and washed in gassed HEPES-buffered Ringer`s solution immediately. To avoid mucus 
secretion the duodenum was additionally washed in HEPES-buffered Ringer`s solution 
containing dimeticon (Sab Simplex, Pfizer GmbH, Berlin, Germany) and acetylcystein 
(MW 163.2 g/mol; ACC 300 mg / 3mLHexal AG, Holzkirchen, Germany). Plastic rings were 
then fixed with tissue glue (Histoacryl® Gewebekleber, Braun, Aesculap AG, Tuttlingen 
Germany) on the mucosal side of the duodenum (Fig. 10) and vertically mounted in the 
Ussing chamber. Both chamber sides were filled with 5 mL HEPES solution containing 
2.14 g substrate mixture (Hydroxybutyrate 1.26 g, L-glutamin 7.3 g, D+-mannose 36.04 g, 
glucose monohydrat 39.6 g, piperacillin 1.0 g, Zienam 0.2 g supplemented with HEPES 
solution to a total amount of 20 L) at a pH of 7.4 and heated up to 37°C. Both chamber sides 
were permanently gassed with a mixture of 95% O2 and 5% CO2. 
 
 
 
 
 
 
 
Figure 10: Rat duodenum tissue preparation. 
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6.3 Behavioral experiments 
6.3.1 Animals 
Male Wistar rats (200 – 250 g) (Harlan Laboratories, Netherlands) were housed in groups 
(three rats / cage). The cages were lined with ground corncob bedding. Rats were kept in 
climate- and light-controlled rooms (22 ± 0.5°C; relative humidity, 60 – 65%; 12 h light / dark 
cycle) with standard rodent food pellets and water ad libitum. Animal protocols were 
approved by the local animal care committee (Landesamt für Arbeitsschutz, 
Gesundheitsschutz und Technische Sicherheit, Berlin, Germany; G 0340/10) and were in 
accordance with the guidelines of the International Association for the Study of Pain 
(Zimmermann, 1983). All efforts were made to minimize the number of animals used and 
their suffering.  
6.3.2 Complete Freund's adjuvant-induced inflammation 
Under brief isoflurane anesthesia rats received unilateral intraplantar (i.pl.) injections of 
150 µL complete Freund's adjuvant (CFA) into the right hind paw as described (Stein et al., 
1988b) (Fig. 11). Rats were handled daily to get used to the experimenter and to reduce stress. 
To this end, rats were carefully placed under tissue wadding and held in this position for at 
least 30 seconds. This procedure was repeated twice per day with each animal. Experiments 
were conducted four days after inoculation. 
 
 
 
 
Figure 11: Inflamed (right) and non-inflamed rat paw (left) on day four after CFA injection.  
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6.3.3 Test compounds 
Intravenous (i.v.) injections were administered into the tail vein. Loperamide hydrochloride 
(1, 5 and 10 mg/kg) was dissolved in 20% DMSO. Morphine sulfate (1, 2.5 and 5 mg/kg), 
dissolved in 0.9% NaCl, was used as a positive control. Control group received 20% DMSO 
i.v.. The oral administration of loperamide hydrochloride and morphine sulfate was performed 
with a metal feeding needle (gauge 15, length 78 mm, ball OD 2.9 mm) into the stomach in 
volumes of 1 mL per animal. To avoid regurgitation, rats did not receive food the night before 
the experiments but had free access to water. For oral administration loperamide 
hydrochloride was dissolved in 10% ethanol and morphine sulfate was solved in saline. 
Control groups received 1 mL of 10% ethanol solution. Chitosan was solved in a 1:40 
solution of acetic acid plus ddH2O and 500 µL at different concentrations for oral 
administration 30 min before loperamide hydrochloride or morphine sulfate. Both i.v. and oral 
administrations were performed under brief isoflurane anesthesia. 
6.3.4 Assessment of nociceptive thresholds 
Mechanical nociceptive thresholds were assessed using the paw pressure algesiometer 
(modified Randall-Selitto test; Ugo Basile) as previously described (Brack et al., 2004b; Stein 
et al., 1988b). Rats were handled for 4 days before testing. Rats were gently restrained under 
paper wadding, and increasing pressure was applied via a wedge-shaped, blunt piston onto the 
dorsal surface of the hindpaw by means of an automated gauge (Ugo Basile, Comerio VA, 
Italy). The pressure required to elicit paw withdrawal was recorded (cutoff at 250 g). The 
average of three consecutive measurements separated by 10 second intervals was calculated 
(Machelska et al., 2003; Stein et al., 1990). Ipsi- and contralateral (non-inflamed) paws were 
tested in alternating sequence. Before drug administrations, baseline thresholds were 
determined in both hindpaws. 
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6.4 Statistical analyzes 
Statistical analyzes for the AS006 and loperamide method validation are described under 
6.7.4.3 and 6.7.5.2. 
Statistical analyzes for Ussing chamber and behavioral experiments were performed using 
GraphPad Prism 5 software. Experiments were repeated at least three times; the numbers of 
experiments used for statistical analysis are given in the figure legends. One- or two-way 
ANOVA was used for multiple groups. If animals were tested repeatedly (e.g. after treatment 
with a different drug), repeated measures (RM) two-way ANOVA were performed. Posthoc 
comparisons were performed with Bonferroni post test when appropriate. A p-value < 0.05 
was considered significant. For non-parametric data Kruskal–Wallis one-way analysis of 
variance and Dunn`s post-test were used.  
To test normality of data distribution the D´Agostino and Pearson omnibus test was used. In 
experiments with an n < 9 it was assumed that data were normally distributed and Two-way 
ANOVA and Bonferroni posttests were used. The Mann–Whitney or Wilcoxon tests were 
used for non-parametric data. The statistical analysis was performed in collaboration with 
André le Blond (INWT Statistics GmbH, Berlin, Germany).  
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7 RESULTS 
7.1 Validation of LC-MS/MS for AS006 
7.1.1 Determination of quantifier and qualifier ion fragments 
The following transitions were monitored (m/z): AS006: 375.2  343.2/227.2; morphine-d3: 
289.3  201.2. The retention time was 2.18 min for AS006 and 3.08 min for the internal 
standard (IS) morphine-d3. 
7.1.2 Specificity 
An interfering signal was defined by a signal/noise ratio > 10, in a time interval of ± 5% of 
the expected retention time of the particular analyte. Two solutions, one with AS006 and one 
with the IS, were measured. With each measurement three mass transitions were chosen, 
(Fig. 12). In Fig. 13, a representative fragmentation spectrum of AS006 and the IS in HEPES-
buffered Ringer's solution is shown. 
 
 
Figure 12: LC-MS/MS fragmentation spectrum of AS006 (A) and morphine-d3 (B). Red ovals indicate the 
m/z of quantifier ion. 
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Figure 13: Representative MRM-chromatogram of AS006 and the IS morphine-d3 in HEPES-buffered 
Ringer's solution. From left to right: peak intensity of AS006 (40 ng/mL, quantifier in blue and qualifier in red) 
and morphine-d3 (quantifier ion in green). The total run time was 5 min. 
7.1.3 Selectivity  
No interfering signals occurred in the selectivity tests, indicating that chitosan had no effect 
on the proper identification of AS006 or the IS. 
7.1.4 Ion suppression test  
Chitosan produced a 33.6% increase of peak area (table 1), indicating that it interfered with 
the analytical method. The AS006 concentration in the sample with chitosan taken from the 
apical side was too high for the calibration curve. Dilution of the samples with HEPES-
buffered Ringer`s solution decreased chitosan concentration as well as interference.  
 
Table 1: Ion suppression induced by chitosan 
 quantifier (Q1)  
(peak area) 
qualifier (Q2) 
 (peak area) 
HEPES plus H2O 1.07 x 104 6.39 x 103 
HEPES plus chitosan 1.43 x 104 9.38 x 103 
 53 
7 Results 
7.1.5 Homogeneity of calibrators  
The standard deviation of relative peak areas was 2.4% for the quantifier ion of AS006 and 
3.5% for the qualifier ion. These deviations fulfill the requirements of the validation protocol 
(RSD ≤ 20%). 
7.1.6 Homogeneity of controls 
The RSD for QC I was not higher than 2.4%, for QC II not higher than 6.1% and for QC III 
8%. Six values for inter-day measurements remained for calculation after the Grubbs test. The 
condition of a bias < 20% and a RSD < 20% was fulfilled for all three QCs.  
7.1.7 Lower limit of quantification  
The detection limit of AS006 in HEPES-buffered Ringer's solution was 0.5 ng/mL, with a 
bias of + 20%, precision of ≤ 20% and a significance level of 99%.  
7.1.8 Definition of measurement range 
The measurement range corresponds to the lower limit of quantification (LLOQ) of 
0.5 ng/mL and the upper limit of linear range of 100 ng/mL. (R ≥ 0.999) 
7.1.9 Accuracy of measurements 
Inter-day bias for QC I was not greater than 1.43%, for QC II not greater than -1.56% and for 
QC III 1.76%. Eight values for inter-day measurements remained for calculation after the 
Grubbs test. The condition of a bias < 20% and a precision < 20% was fulfilled for all three 
QCs.  
7.2 Validation of LC-MS/MS for loperamide 
7.2.1 Determination of quantifier and qualifier ion fragments 
The following transitions were monitored (m/z): loperamide: 477.3  266.3/210.2; IS 
(methadone-d3): 313.3  268.3 (Fig. 14). The retention time was 1.81 min for loperamide and 
1.72 min for methadone-d3. 
 
 54 
7 Results 
Figure 14: LC-MS/MS fragmentation spectrum of loperamide (A) and methadone-d3 (B). Red ovals 
indicate the m/z of quantifier and qualifier ion. 
7.2.2 Specificity 
An interfering signal was defined by a signal/noise ratio > 10 in a time interval of ± 5% of the 
expected retention time of the particular analyte. No interfering signals occurred. In Fig. 15, a 
representative MRM-chromatogram of loperamide and the IS methadone-d3 in HEPES-
buffered Ringer's solution is shown.  
 
 
 
 
 
 
 
Figure 15: Representative MRM-chromatogram of loperamide (50 ng/mL) and the IS methadone-d3 in 
HEPES-buffered Ringer's solution. The quantifier ion of loperamide is shown in blue, the qualifier ion of 
loperamide is shown in red and the quantifier of the IS methadone-d3 is shown in green.  
7.2.3 Selectivity 
Both chromatograms showed no interfering signals. This indicates that the HEPES-buffered 
Ringer's solution had no effect on the identification of the analyte loperamide. 
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7.2.4 Precision and accuracy 
Inter-day bias for QC I was not higher than 13.2% and for QC II not higher than 7.4%. Intra-
day bias for QCI did not exceed 7.4% within a precision of 6.6%, and 14.6% for QCII within 
a precision of 8.2%. Eight values for inter-day and intra-day measurements remained for 
calculation after the Grubbs test. The conditions of precision and bias < 15% were fulfilled for 
both QCs. 
7.2.5 Measurement range 
The LLOQ of loperamide in HEPES Ringer's solution was 0.2 ng/mL within a bias + 20%     
(-5.7%), precision of ≤ 20% (9.8%) and a significance level of 99%. All data points were 
tested for potential outliers using the F-test (significance level 99%). The goodness of fit was 
tested according to Mandel (Neitzel, 2002). The coefficient of correlation (R) was determined 
as well. The detection limit of loperamide in HEPES-buffered Ringer's solution was 
0.1 ng/mL, within a bias + 50% (-48.5%), precision of ≤ 50% (17.7%) and a significance level 
of 95%.  
7.2.6 Matrix effect  
During post column infusion the signal intensity for loperamide and methadone-d3 did not 
change indicating that no ion suppression or enhancement occurred (Fig. 16). 
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Figure 16: Ion-suppression profiles. Ion chromatograms for qualifier (A) and quantifier (B) of loperamide 
(LOP) and quantifier of methadone-d3 (C), comparison between HEPES-buffered Ringer`s solution and blank 
solution of ddH2O. The arrow indicatesthe expected loperamide peak on the x-axis (retention time).  
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7.2.7 Stability 
The peak area values of the two untreated QC samples and those subjected to three 
freeze/thaw cycles did not differ over at least 6 h. The means of the pretreated samples (QCI 
7.7 and QCII 92.7 ng/mL) were within a ± 10% interval of the mean of the untreated samples 
(QC I 7.4 and QC II 89 ng/mL). The 90% confidence interval was within a ± 20% interval of 
the mean of untreated samples.  
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7.3 Ussing chamber experiments with AS006 
Monolayer filters of HT29/B6 and Caco-2 cells were used and AS006 and loperamide 
concentrations were determined in samples collected from the basolateral and apical side. 
7.3.1 Effect of chitosan on permeability of HT29/B6 cell monolayers 
The TER of HT29/B6 cell monolayers was determined continuously over a time period of 
120 min. Four representative time points including time point zero (baseline) are shown in 
Fig. 17. After TER reached a stable baseline value, chitosan or vehicle (acetic acid) were 
added. After 30 min, the TER decreased significantly and to similar degrees at doses of 
0.3 µM, 1 µM and 3 µM chitosan compared to vehicle (two-way RM ANOVA, p < 0.001). In 
cell monolayers treated with 1 µM and 3 µM chitosan the resistance showed a time-dependent 
decrease that was not observed at lower chitosan doses. At 0.30, 1.00 and 3.00 µM chitosan 
significantly drecreased the TER at 120 min compared to time point zero (one-way ANOVA, 
p < 0.05 and p < 0.001). In vehicle treated cells, the TER did not differ between the time 
points investigated (one-way ANOVA, p > 0.05).   
 
Figure 17: Effect of chitosan on the TER of HT29/B6 cell monolayers. Data represent means ± SEM, 
baseline TER was set to 100%. Statistical analysis was performed with two-way RM ANOVA, t-test and 
Bonferroni correction for multiple comparisons, ***p < 0.001 and **p < 0.01, compared to vehicle. 
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Next, the effect of chitosan on intestinal transport of AS006 was analyzed.  
The AS006 concentration on the basolateral side increased with time in all five chambers 
(Fig. 18). A marked increase of AS006 concentrations was observed after 60 and 120 min 
incubation with 1 µM and 3 µM chitosan (p < 0.001, respectively). The strongest increase was 
found for 3 µM chitosan after 120 min representing a 0.6% permeation rate of AS006 applied 
to the apical side. At 120 min chitosan-induced permeation was dose dependent (linear 
regression coefficient 0.95). On the apical side the AS006 concentration 
(mean 12.23 ± 0.64 µg/mL) did not change significantly during the experiments.  
 
Figure 18: Time- and dose-dependent effect of chitosan on the basolateral concentration of AS006. Data 
represent mean AS006 concentrations ± SEM in ng/mL. Statistical analysis was performed with two-way RM 
ANOVA, t-test and Bonferroni correction for multiple comparisons, ***p < 0.001, compared to vehicle. 
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Permeability P was determined using basolateral and apical AS006 concentrations (see 
chapter 6.2.10). The permeability of AS006 was significantly increased by 1 µM and 3 µM 
chitosan compared to vehicle (p < 0.05, p < 0.01, p < 0.001, respectively), but not by 0.15 µM 
or 0.3 µM chitosan (Fig. 19).  
 
Figure 19: Effect of chitosan on AS006 permeability of HT29/B6 cell monolayers. Data represent the mean 
permeability P of AS006 + SEM in cm/sec. Statistical analysis was performed with two-way RM ANOVA,        
t-test and Bonferroni correction for multiple comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, compared to 
vehicle.  
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7.3.2 Effect of chitosan on permeability of Caco-2 cell monolayers 
First, TER was measured over 120 min (Fig. 20). The TER decreased over time at all four 
chitosan concentrations, whereas the TER of controls (acetic acid) did not change over 
120 min. 1 µM and 3 µM chitosan induced the strongest decrease in TER after 60 and 
120 min (p < 0.05, p < 0.01, p < 0.001) compared to vehicle. 0.15 µM and 0.3 µM chitosan 
did not induce significant changes compared to vehicle. 0.3, 1 and 3 µM chitosan significantly 
decreased the TER from time point zero to 120 min (one-way ANOVA, p < 0.05 and 
p < 0.001). 
 
Figure 20: Time- and dose-dependent effect of chitosan on TER of Caco-2 cell monolayers. Data represent 
means ± SEM. Statistical analysis was performed with two-way RM ANOVA, t-test and Bonferroni correction 
for multiple comparisons, ***p < 0.001, **p < 0.01 and *p < 0.05, compared to vehicle. 
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AS006 concentrations in the basolateral compartment increased over 120 min at all chitosan 
doses (Fig. 21). At 120 min 1 µM and 3 µM chitosan induced a marked increase of AS006 
concentration compared to vehicle (acetic acid) (p < 0.001, respecively). 1 µM and 3 µM 
chitosan induced a similar increase of AS006 permeation after 120 min.  
 
Figure 21: Time- and dose-dependent effect of chitosan on the basolateral concentration of AS006. Data 
represent mean AS006 concentrations ± SEM in ng/mL. Statistical analysis was performed with two-way RM 
ANOVA, t-test and Bonferroni correction for multiple comparisons, ***p < 0.001, compared to vehicle. 
 
On the apical side AS006 concentrations remained stable over 120 min (mean + SEM: 
13.39 µg/mL + 1.56 µg/mL).  
For the calculation of AS006 permeability, the apical and basolateral concentrations were 
used as described in chapter 6.2.10. 
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Incubation with 0.15 µM and 0.3 µM chitosan did not significantly increase permeability. 
After 120 min, 1 µM and 3 µM chitosan induced a marked increase in AS006 permeability 
(p < 0.01, respectively; Fig. 22). 
 
Figure 22: Effect of chitosan on the AS006 permeability of Caco-2 cell monolayers. Data represent the mean 
permeability P of AS006 + SEM in cm/sec. Statistical analysis was performed with two-way RM ANOVA,        
t-test and Bonferroni correction for multiple comparisons, **p < 0.01, compared to vehicle. 
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7.4 Ussing chamber experiments with loperamide  
7.4.1 Effect of chitosan on the permeability of HT29/B6 cell monolayers 
Chitosan induced the same decrease in TER as already shown in Fig. 17. For the loperamide 
transport studies, one additional chitosan concentration (0.075 µM) was tested (Fig. 23). This 
did not affect TER. The loperamide concentration increased after 120 min in all chambers. A 
significant increase compared to the vehicle (acetic acid) was found with 1 µM and 3 µM 
chitosan (p < 0.01 and p < 0.05), no dose-dependency was observed. 
 
Figure 23: Time- and dose-dependent effect of chitosan on the basolateral concentration of loperamide. 
Data represent the mean loperamide concentration ± SEM in ng/mL. Statistical analysis was performed with 
two-way RM ANOVA, t-test and Bonferroni correction for multiple comparisons, *p < 0.05, **p < 0.01, 
compared to vehicle. 
 
On the apical side the loperamide concentrations remained stable (mean + SEM: 20.79 µg/mL 
+ 4.29 µg/mL) in all groups over 120 min. To calculate permeability, loperamide 
concentrations on the apical side before treatment with chitosan and the basolateral 
loperamide concentrations after 120 min were used as described in chapter 6.2.10.  
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Permeability of cell monolayers treated with 1 µM and 3 µM chitosan showed a slight 
(nonsignificant) increase, otherwise loperamide permeability was unchanged compared to 
vehicle (Fig. 24).  
 
 
Figure 24: Effect of chitosan on loperamide permeability of HT29/B6 cell monolayers after 120 min. Data 
represent the mean permeability P of loperamide + SEM in cm/sec (n = 4 per chitosan concentration (conc.). 
Statistical analysis was performed with one-way ANOVA.  
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7.4.2 Effect of chitosan on permeability of Caco-2 cell monolayers 
Chitosan influenced TER in the same way as shown in Fig. 20. One additional chitosan 
concentration (0.075 µM) was tested, which had no effect on the TER. No chitosan 
concentration had significant effects on loperamide permeability (Fig. 25). A small 
(nonsignificant) increase in basolateral loperamide concentration (compared to vehicle) was 
observed using 3 µM chitosan. 
 
Figure 25: Time- and dose-dependent effect of chitosan on the basolateral concentration of loperamide. 
Data represent the mean loperamide concentration ± SEM in ng/mL. Statistical analysis was performed with 
two-way RM ANOVA, t-test and Bonferroni correction for multiple comparisons of values at 120 min to vehicle 
at 120 min.  
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On the apical side loperamide concentrations remained unchanged (mean + SEM: 
19.17 µg/mL + 8.47 µg/mL) in all groups over 120 min. To calculate permeability, the 
loperamide concentration on the apical side before treatment with chitosan and the basolateral 
loperamide concentrations were used as described in chapter 6.2.10.  
Permeability P for loperamide did not significantly change at any chitosan concentration 
(Fig. 26). 
 
Figure 26: Effect of chitosan on loperamide permeability coefficiets of Caco-2 cell monolayers after 
120 min. Data represent the permeability P of loperamide + SEM in cm/sec (n = 4 per chitosan concentration 
(conc.). Statistical analysis was performed with one-way ANOVA.  
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7.5 Effect of chitosan on the permeability of rat duodenum 
The duodenum was divided into four consecutive sections with section 1 representing the 
most proximal region. After TER reached stable baselines (set as 100%), chitosan (sections 
1 and 3) or vehicle (sections 2 and 4) were added to the apical side and TER was measured 
over 180 min (Fig. 27). 
 
Figure 27: Effect of chitosan on TER of rat duodenum. Data represent the results of one experiment, baseline 
values were set as 100%.    
The resistance in all four sections decreased over time. Section two, treated with vehicle, 
showed the strongest decrease (53%) in TER. Chitosan reduced the TER in section 1 by 31% 
and in section four by 26%. In section three, treated with vehicle, the TER decreased by 32%. 
Subsequently, two higher chitosan concentrations were tested (3.0 µM and 6.0 µM) but none 
of these affected TER. The application of chitosan to both chamber sides did not affect the 
TER either. The addition of acetylcysteine and dimeticon to decrease mucus and frothing 
formation on the apical side of the tissue did not result in significant improvement. In 
summary, chitosan did not significantly decrease TER of duodenum compared to vehicle. 
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7.6 Behavioral experiments 
7.6.1 Intravenous injection of morphine sulfate and loperamide 
The antinociceptive effects of several different doses of intravenously (i.v.) injected morphine 
sulfate and loperamide were evaluated in preliminary pilot experiments using the paw 
pressure test. The experiments were conducted in small groups (n = 2 - 6) four days after CFA 
injection into the right hindpaw. Before drug injections (time zero), the baseline paw pressure 
thresholds (PPT) were determined and were measured repeatedly over 120 min thereafter.  
In the non-inflamed hindpaws (Fig. 28 A) i.v. morphine sulfate (5 mg/kg) induced significant 
PPT elevations (p < 0.01) lasting for 60 min, whereas 10 mg/kg loperamide and 20% DMSO 
were ineffective. In the inflamed hindpaws (Fig. 28 B), both 5 mg/kg morphine sulfate and 
10 mg/kg loperamide induced significant (p < 0.01 and p < 0.001) increases in PPT. The 
effect of morphine sulfate lasted for 60 min, the effect of loperamide for about 30 min.   
 
Figure 28: Effects of i.v. loperamide, morphine sulfate and vehicle (20% DMSO) on paw pressure 
thresholds (PPT) in non-inflamed (A) and inflamed (B) hindpaws. Data represent % of baseline (BL) 
(means ± SEM, left y-axis) and their corresponding PPT in gram (g, right y-axis). The BL was calculated as 
mean of all vehicle data (A: 87 g, B: 39 g). Statistical analysis was performed on raw PPT values with two-way 
RM ANOVA, t-test and Bonferroni correction for multiple comparisons. **p < 0.01, ***p < 0.001, compared to 
vehicle. 
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7.6.2 Oral administration of morphine sulfate and loperamide 
Orally administered morphine sulfate induced dose-dependent PPT elevations (Fig. 29 C: 
R² = 0.72; Fig. 29 D:  R² = 0.97, determined by linear regression ANOVA on areas under the 
curve (AUC) of raw PPT values) in both paws. As shown by PPT elevations in % of baseline 
(BL), the effects were significantly higher in inflamed than in noninflamed paws and lasted 
for about 120 min (Fig.29). 
 
 
Figure 29: Effect of oral morphine sulfate and control (10% EtOH) on PPT in non-inflamed (A, C) and 
inflamed (B, D) hindpaws. Data represent % BL (means ± SEM, left y-axis) and their corresponding PPT in 
gram (g, right y-axis). The BL was calculated as mean of all vehicle data (A: 77 g, B: 41 g). Statistical analysis 
was performed on raw PPT values with two-way RM ANOVA, t-test and Bonferroni correction for multiple 
comparisons. **p < 0.01, ***p < 0.001, compared to control. Bar graphs show the total AUC of PPT values (g) 
shown in (A) and (B). Data in C and D represent mean total AUC ± SEM over the time period of 120 min. 
Statistical analysis was performed with linear regression ANOVA (C: R² = 0.72; D: R² = 0.97). 
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Orally administered loperamide induced dose-dependent PPT elevations (Fig. 30 C: 
R² = 0.70; Fig. 30 D: R² = 0.93, determined by linear regression ANOVA on AUC of raw 
PPT values) in inflamed paws and a much smaller effect (only at the highest dose) in 
noninflamed paws. The effects lasted for about 30 min (Fig. 30). 
 
Figure 30: Effects of oral loperamide and vehicle (10% EtOH) on PPT in non-inflamed (A, C) and 
inflamed (B, D) hindpaws. Data represent % BL (means ± SEM, left y-axis) and their corresponding PPT in 
gram (g, right y-axis). The BL was calculated as mean of all vehicle data (A: 77 g, B: 41 g). Statistical analysis 
was performed on raw PPT values with two-way RM ANOVA, t-test and Bonferroni correction for multiple 
comparisons. **p < 0.01, ***p < 0.001, compared to vehicle. Bar graphs show the total AUC of PPT values (g) 
shown in (A) and (B). Data in C and D represent mean total AUC ± SEM over the time period of 120 min. 
Statistical analysis was performed with linear regression ANOVA (C: R² = 0.70; D: R² = 0.93). 
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7.6.3 µ-opioid receptor antagonist (NLXM) in combination with orally administered 
loperamide  
To following experiments were performed to identify the site of action of loperamide 
(Fig. 31). The µ-opioid receptor antagonist NLXM was injected subcutaneously (s.c.) 10 min 
before oral adminstration of loperamide. When applied systemically, NLXM does not cross 
the blood-brain barrier, which helps to distinguish between centrally and peripherally 
mediated analgesic effects. In the non-inflamed paw neither loperamide nor combinations 
with NLXM induced significant changes on PPT. In the inflamed paw loperamide produced 
significant PPT elevations which were reduced by 2.5 and 5 mg/kg (but not by 10 mg/kg) of 
NLXM (Fig. 31). 
 
Figure 31: Effects of NLXM on PPT elevations induced by loperamide (LOP) in the non-inflamed (A) and 
inflamed (B) hind paw. Data represent mean PPT ± SEM. Statistical analysis was performed with one-way 
ANOVA, t-test and Bonferroni correction for multiple comparisons. Loperamide-induced PPT elevations 
compared to BL were similar in groups receiving vehicle (saline) and 10 mg/kg NLXM (*p < 0.05; **p < 0.01). 
PPT after 2.5 and 5 mg/kg NLXM were not significantly different from BL (p > 0.05). 
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7.6.4 Oral administration of loperamide in combination with chitosan 
Following a number of pilot experiments to determine optimal dosage and time intervals, 
chitosan (or its vehicle acetic acid) was given orally 30 min before oral loperamide (5 mg/kg) 
administration and PPT were measured repeatedly thereafter. 
In the non-inflamed hindpaws (Fig. 32 A), small but significant elevations of PPT were 
observed for vehicle (p < 0.05) and 3% chitosan (p < 0.001) compared to control (3.0% 
chitosan plus 10% EtOH) (Fig. 32 A, C). Compared to vehicle (acetic acid), none of the 
chitosan concentrations increased the effect of loperamide (Fig. 32 A, C). In the inflamed 
hindpaws (Fig. 32 B, D) the loperamide-induced PPT elevations were significantly increased 
in animals treated with 0.5% and 3.0% chitosan compared to the control group (3.0% chitosan 
plus 10% EtOH) at 10 min (p < 0.01). Compared to vehicle (acetic acid), none of the chitosan 
concentrations increased the overall effect of loperamide (Fig. 32 B, D). Only at 10 min the 
effect of loperamide was slightly but insignificant increased by 0.5 % and 3.0 % chitosan 
compared to vehicle (aa) plus loperamide. 
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Figure 32: Effects of oral chitosan or its vehicle (aa = acetic acid) in combination with oral loperamide 
(LOP) or its vehicle (10% EtOH) on the PPT in non-inflamed (A, C) and inflamed (B, D) hindpaws. Data 
represent % BL (means ± SEM, left y-axis) and their corresponding PPT in gram (g, right y-axis). The BL was 
calculated as mean of all vehicle data (A: 70 g and B: 45 g). Statistical analysis was performed on raw PPT 
values with two-way RM ANOVA, t-test and Bonferroni correction for multiple comparisons. **p < 0.01, 
***p < 0.001, compared to control (10% EtOH). Bar graphs show the total AUC of PPT values (g) shown in (A) 
and (B). Data in C and D represent mean total AUC ± SEM over the time period of 300 min. Statistical analysis 
was performed with Kruskal-Wallis test, t-test and Dunn´s multiple comparsion test. *p < 0.05 and **p < 0.01 
compared to control (10% EtOH). 
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8 DISCUSSION 
Peripheral opioid receptors can mediate pain relief without unwanted CNS side effects (Stein 
et al., 1988a; Stein et al. 2003). Thus, several opioid analgesics with restricted ability to cross 
the blood brain barrier have been designed (Stein and Machelska, 2011). However, intestinal 
epithelial permeability limits the effective oral administration of such compounds. The 
objective of this work was to evaluate the intestinal epithelial permeability of peripherally 
acting µ-opioid receptor agonists (AS006, loperamide) in combination with the absorption 
enhancer chitosan, and to investigate the impact of chitosan on the analgesic effect of these 
opioids when applied orally.  
The major findings are: I) Chitosan increased the permeability of AS006 in HT29/B6 and 
Caco-2 cell monolayers in vitro. II) Loperamide showed moderate ability to cross HT29/B6 
monolayers that slightly increased in the presence of chitosan in vitro. Chitosan had no effect 
on the permeability of loperamide in Caco-2 cell monolayers. III) In vivo, both i.v. and oral 
morphine sulfate and loperamide produced antinociceptive effects that were stronger in 
inflamed compared to noninflamed tissue. The effects of orally administered morphine sulfate 
and loperamide were dose-dependent and those of loperamide were reduced by the 
peripherally restricted opioid receptor antagonist NLXM. IV) The addition of oral chitosan 
slightly (but nonsignificantly) enhanced the peak antinociceptive effect of oral loperamide in 
vivo.  
8.1 Validation of LC-MS/MS method  
For the distinctive detection of AS006 and loperamide, two new LC-MS/MS methods were 
developed and validated (Rubelt et al., 2012). A HPLC combined with a MS/MS was used to 
achieve detection within a high sensitivity and selectivity. This relatively new analytical 
technology provides high accuracy and specificity, and helps to achieve  high-throughput of 
sample measurements with increased data quality (Chen et al., 2000; Jian et al., 2010; Rubelt 
et al., 2012; Youdim and Saunders, 2010). In comparison to immune-assay techniques like 
enzyme linked immunosorbent assay and radioimmunoassay (Michiels et al., 1977; Killinger 
et al., 1979), the LC-MS/MS technique is much faster, samples can be quantified within 
minutes instead of hours or days. In addition, it has higher intraclass correlation coefficients, 
lower coefficients of variation (Faupel-Badger et al., 2010), and less cross reactivity regarding 
metabolites. 
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LC-MS/MS does have limitations. For example, complex matrix solutions like the organic 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-buffered Ringer's solution, which 
was used during in vitro studies present here, have high salt concentrations, which can 
interfere with a proper detection of the analyte of interest. Interferences such as ion 
suppression can occur due to the sample matrix, coelution of compounds, and cross-talk. 
Previous studies have shown that one of the major causes of ion suppression is a change in the 
spray droplet solution properties caused by the presence of nonvolatile (e.g., salts, ionpairing 
agents, endogenous compounds, drugs/metabolites) or low volatile solutes (King et al., 2000). 
To analyze if ion suppression was provoked using a physiological concentration of salts in the 
buffer solution (HEPES) and would affect the analyte quantification, post column analyzes 
were conducted. The post column infusion applied directly to the MS did not change the 
signal intensity of the target analytes, which indicated that no ion suppression or enhancement 
occurred.  
The newly developed detection method for AS006 was designed to detect even low (ng/mL) 
AS006 concentrations in HEPES-buffered Ringer`s solution with a high reproducibility. For a 
distinctive detection of AS006, the mass spectrometer was set to scan a specific mass range 
regarding the molecular weight of AS006. For scanning and acquiring MS data, the well-
established MRM scanning mode was used (Ding et al., 2013; Wang, 2009; Yang et al., 
2012). MRM is an appropriate method for monitoring single fragment ions in complex matrix 
solutions. For specific detection of the target analyte, the fragment ions with the highest peak 
mass were chosen. As an internal positive control the IS morphine-d3 was found to be 
suitable. Morphine-d3 was chosen because of its high chemical similarity to the target analyte 
AS006. The lower limit of quantification was 0.5 ng/mL AS006. Lower concentrations of 
AS006 were not detectable with a clear signal from the MS. The efficiency of this method 
was enhanced by a switching valve, which was introduced to minimize the column 
contamination and to reduce its high abrasion. A simple sample preparation protocol by just 
adding the internal standard morphine-d3, combined with a short mixing time proved to be 
sufficiently fast and easy and revealed a standard curve with a linear regression coefficient 
close to 1 (R ≥ 0.999).  
 
Previously, LC-MS/MS methods were only available for the detection of loperamide in mouse 
serum and brain tissue and human plasma (He et al., 2000; Kalvass et al., 2007) but not in 
HEPES-buffered Ringer's solution. Therefore it was necessary to develop a new method. No 
interfering signals occurred, ensuring a specific detection of the analyte. The validation data 
 77 
8 Discussion 
revealed reliable and reproducible results according LC-MS/MS guideline requirements 
(Peters et al., 2009, 2007), covering a loperamide concentration range from 0.2 to 100 ng/mL. 
The use of two mass transitions as well as specific retention time as criteria for quantification 
and identification reduces the risk of interferences and enhances specificity. Sample 
preparation is convenient and cost effective because of the short run time and suitable for high 
throughput. Sample workup by just adding the IS methadone-d3 with a short mixing time and 
centrifugation time of 5 min proved to be sufficiently fast and easy. No interfering signals and 
no matrix effects occurred during the analyzes using methadone-d3, which indicates that it is a 
suitable internal standard. Sample preparation with acetonitrile followed by centrifugation of 
the samples insured a clear solution (due to the precipitation of proteins and salt). This way of 
sample preparation revealed a standard curve with linear regression coefficients close to 
1 (R ≥ 0.995). In summary, this assay achieved a high specificity and sensitivity even for 
small amounts of loperamide. The short run time of 3 min compares favorably to other assays 
(He et al., 2000), and it uses a fast and easy sample preparation protocol.  
The detection of loperamide and AS006 in HEPES buffered Ringer´s solution is useful for 
several in vitro studies, for example cell culture experiments within the same matrix. 
Furthermore, in vivo approaches can benefit from this LC-MS/MS detection protocol. 
Variations of single parameters are marginal compared to the effort of the development of a 
full detection protocol. 
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8.2 Ussing chamber experiments 
Ussing chamber experiments were conducted to test intestinal permeability of AS006 and 
loperamide, and the influence of chitosan in vitro, in line with the “3R” (“Refine, Reduce, 
Replace”) concept to decrease the number of in vivo animal experiments (Go3R, 2012; Grune 
et al., 2004; Russell WMS and Burch RL., 1959). Two epithelial human colon cell lines, 
Caco2- and HT29/B6, which are frequently used for intestinal permeability studies (Amasheh 
et al., 2012; Kowalik et al., 2004; Kreusel et al., 1991; Merzlikine et al., 2009; Moran et al., 
2012; Press and Di Grandi, 2008) were investigated.  
8.2.1 Stability of AS006 and loperamide in Ussing chambers  
LC-MS/MS assays established that the AS006 and loperamide concentrations added to the 
apical side of the Ussing chamber were generally stable over a time period of 120 min in all 
experiments. This indicated that these substances were not degraded by ultraviolet light or 
enzymatic cleavage and were not affected by the Ussing chamber system. Absorbance by the 
cell monolayers and interaction with the HEPES Ringer`s solution was also excluded for this 
time frame. The pH drop induced by addition of chitosan and vehicle (acetic acid) solution 
had no effect on the apical AS006 and loperamide concentrations either. Freeze/thaw stability 
for both substances was checked during the LC-MS/MS method validation and no 
disintegrations were observed. Only the intact molecule can bind to the stationary phase and is 
afterwards forwarded to the MS, where it is fragmented and detected. Consequently, no 
degraded molecules can be detected by the LC-MS/MS method. In conclusion, the Ussing 
chamber system in combination with the HEPES Ringer`s solution provides a suitable system 
for permeability studies of AS006 and loperamide. Only minor variations in the 
concentrations might be explained by the distribution system of the Ussing chambers. 
8.2.2 Chitosan effect on epithelial resistance 
A decrease in TER usually indicates a higher permeability for ions and larger molecules, as 
shown in previous studies using the same cell systems (Amasheh et al., 2008; Rosenthal et al., 
2012b). In the presence of chitosan, the TER decreased significantly over time, which is likely 
induced by the enhanced transport of ions through the paracellular gap and indicates an 
opening of the TJs. The maximal effect of chitosan on the TER occurred after 30 min for both 
cell monolayers. The underlying mechanism involves the adhesion of chitosan to the TJs of 
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neighboring epithelial cells. As previously shown by others, chitosan is positively charged 
and has the ability to bind to negatively charged groups of TJ proteins (Aungst, 2000). This 
interaction results in a structural modification of the TJs that increases space between 
neighboring epithelial cells. Rosenthal and colleagues found that this decrease in resistance 
can be blocked by the addition of heparin, which is negatively charged and thus competes 
with the negatively charged groups of the TJ proteins (Rosenthal et al., 2012b). Similar to 
those findings, in pilot experiments heparin reversed the chitosan effect on TER (data not 
shown). Taken together, chitosan decreased the TER of HT29/B6 and Caco-2 cell monolayers 
in Ussing chambers indicating that the epithelial barrier was opened in agreement with 
previous studies (Borchard et al., 1996; Merzlikine et al., 2009; Rosenthal et al., 2012b; Yeh 
et al., 2011).  
  
8.2.3 AS006 permeability of epithelial cell monolayers is augmented by chitosan 
The µ-opioid receptor agonist AS006 has a strong polar structure due to its zwitterionic 
character and the presence of a glycine residue at C-6 of the morphinan scaffold. This polar 
structure restricts permeation across the blood-brain barrier (Schütz et al., 2003) and intestinal 
barriers (Gad, 2008). This was reflected by the marginal permeation of AS006 from the apical 
to the basolateral side of HT29/B6 and Caco-2 cell monolayers (< 5 ng/mL) determined here 
in vehicle treated Ussing chambers. However, AS006 permeated when the TER dropped after 
adding 1 - 3 µM chitosan to both cell monolayers. Lower chitosan concentrations (0.15 and 
0.3 µM) also decreased the TER but the permeability values of AS006 were indistinguishable 
from vehicle controls. Apparently, the enhanced passage of ions, reflected by the decrease in 
TER, does not directly correlate with permeation of AS006. In accordance with the present 
findings, low chitosan concentrations have previously been found ineffective while 1 - 3 µM 
chitosan also enhanced the transport of other hydrophilic compounds such as [3H]-mannitol 
and FITC-dextran (Rosenthal et al., 2012b). These authors also demonstrated that the 
maximum size of polar molecules passing via the paracellular path after addition of chitosan 
was 10 kDa (Rosenthal et al., 2012b). As AS006 has a molecular weight of only 374.4 Da, it 
should easily pass paracellularly if size was the only restriction.  
By use of 3 μM and 1 μM of chitosan, the AS006 concentrations on the basolateral side of 
HT29/B6 cell monolayers were significantly increased after 60 min and 120 min. Using  
Caco-2 cell monolayers, the basolateral AS006 concentration was significantly increased after 
120 min. Higher chitosan concentrations damaged the epithelial cell monolayer irreversibly. 
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Rosenthal and co-workers (2012b) performed most of their experiments using 1 µM (0.005%) 
chitosan, since they found enhanced lactate dehydrogenase activity at higher concentrations. 
This cytosolic enzyme is released into the medium when cells are injured and therefore acts as 
a marker of cytotoxicity. Cells exposed to a 3 µM (0.015%) chitosan solution, however, were 
able to recover within 24 h. Taken together, 3 µM appears to be the maximum dose 
recommendable in vitro. Chitosan derivatives seem to be of lower toxicity. For example, 
Merzlikine and colleagues found that 3.0% chitosan glutamate enhanced paracellular passage 
of acyclovir (log P = −1.59) in vitro using Caco-2 cells (Merzlikine et al., 2009). Kudsiova 
and Lawrence showed that chitosan-coated phospholipid vesicles caused a decrease in TER 
and increased the permeability of FITC-dextran to a similar degree as seen using chitosan 
solution. In this study, the chitosan-coated phospholipid vesicles and the chitosan solution 
were both tolerated well by Caco-2 cells but the vesicles had a lower toxic effect on 
16HBE14o-cell monolayers (Kudsiova and Lawrence, 2008). Chitosan nanoparticles, 
however, were of similar toxicity for Calu-3 cells as chitosan solution and did not enhance the 
passage of FITC-dextrans (Vllasaliu et al., 2010). Together these findings demonstrate that 
chitosan is a potent absorption enhancer of AS006 and other polar compounds, but at high 
doses it can lead to cell damage. 
A parameter to describe the passage of a drug across an epithelial barrier is the permeability 
value. The permeability reflects the rate of drug movement into the receiver compartment 
(basolateral side) depending on the drug concentration on the apical side and the area of the 
cell filter membrane (Hernández-Covarrubias et al., 2012; Kataoka et al., 2011; Yamashita et 
al., 2002). According to previous studies (Fichert et al., 2003; Kaldas et al., 2003), 
compounds with permeability values < 0.3 × 10-6 cm/s, between 0.3 × 10-6 and 10 × 10-6 cm/s, 
and > 10 × 10-6 cm/s are defined as poorly, moderately, and highly permeable, respectively. 
Using HT29/B6 cell monolayers, AS006 permeability values were significantly increased 
from a poor (0.5 × 10-6 cm/s) up to a moderate permeability (7 × 10-6cm/s) using 1 µM and 
3 µM chitosan. These findings are comparable to those of Rosenthal et al., 2012b, who 
studied the transport of mannitol (5 × 10-6 cm/s) and dextrane (0.9 × 10-6 cm/s) in 
combination with chitosan. In Caco-2 cells the permeability values for AS006 increased only 
from 0.3 × 10-6 cm/s to 2.4 × 10-6 cm/s using 3 µM chitosan. Thus, HT29/B6 cell monolayers 
showed a better permeability for AS006. This difference may be explained by structural or 
functional differences between these cell types. For example, HT29/B6 cells secrete more Cl- 
than Caco-2 cells (Kreusel et al., 1991). In addition, chloride-bicarbonate exchangers may be 
involved in chitosan-induced opening the paracellular pathway (Rosenthal et al., 2012b). In 
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conclusion, chitosan is an efficient enhancer of the intestinal paracellular passage of 
hydrophilic molecules including AS006 in vitro. 
8.2.4 Permeability of loperamide across the intestinal barrier augmented by chitosan      
In contrast to AS006, loperamide is a highly hydrophobic molecule (log P 4.26) and 
sequestered in lipid membranes. Unlike AS006, loperamide is a substrate of the efflux 
membrane transporter P-gp (Ooms et al., 1984; Thiebaut et al., 1987b). These two features 
keep loperamide from passing the blood-brain barrier (Schinkel et al., 1996b) despite its 
hydrophobic character.  
Without chitosan treatment, the basolateral amount of loperamide increased 2- and 4-fold 
within 120 min using HT29/B6 and Caco-2 cell monolayers, respectively. These data indicate 
that hydrophobicity and P-gp active transport do not completely prevent the passage of 
loperamide across intestinal cell monolayers. In the present study pilot experiments addressed 
the effect of quinidine, another P-gp substrate that competes with loperamide, but no effect 
was found (data not shown). This is in accordance with previous findings in humans 
(Vandenbossche et al., 2010) and suggests that additional mechanisms are involved in the 
intestinal membrane transport of loperamide, as in MDCKII-hMDR1 cell monolayers 
(Acharya et al., 2008). Examples may be passive diffusion or basolateral transporters, as 
suggested by observations in a human kidney cell line (Agnani et al., 2011).  
Using 0.3, 1 and 3.0 µM chitosan, the loperamide passage through HT29/B6 cell monolayers 
was significantly elevated after 120 min, similar to AS006. However, in Caco-2 cells, the 
loperamide passage was lower and showed an increase only at 3 µM chitosan, although TER 
was already reduced by 1 µM chitosan. As mentioned above, additional mechanisms such as 
chloride-bicarbonate exchangers may contribute to the opening of the paracellular pathway in 
HT29/B6 cell monolayers (Rosenthal et al., 2012b) and may render this cell type more 
permeable for the opioids analyzed here. 
1 µM chitosan increased loperamide permeability in HT29/B6 cells in comparison to 
loperamide alone (4.4 + 0.15 × 10-6 vs. 1.7 + 0.9 × 10-6 cm/s) but both values were in the 
range of moderate permeability and Caco-2 cell monolayers showed only a slight 
(nonsignificant) increase in permeability in the presence of chitosan. Thus, HT29/B6 cells 
showed a better permeability for loperamide both in the presence and absence of chitosan as 
compared to Caco-2 cell monolayers.  
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8.2.5 Chitosan effect on AS006 permeability in rat duodenum          
In rat duodenum the TER decreased over time. This is a common phenomenon (Petersen et 
al., 2012) and most likely reflects the loss of integrity of native tissue after its removal from 
the animal. Chitosan had no additional effect on TER. It is possible that the thick mucus layer 
on the apical surface of the tissue may have hindered chitosan to reach the cell surface, as was 
previously observed by Schippers and colleagues. These authors found that mucus prevents 
the actions of chitosan in rat ileum, which can be overcome by increased drug and chitosan 
concentrations (Schipper et al., 1999). To reduce the amount of mucus, acetylcystein plus 
dimeticon were applied to the apical side but chitosan still had no effect on TER. Chitosan 
may have been bound to mucin proteins (Silva et al., 2012; Sogias et al., 2008). The 
mucoadhesive properties of chitosan have been interpreted as beneficial since these 
interactions increase gastrointestinal residence time and promote the absorption of orally 
administered drugs (Bernkop-Schnürch and Walker, 2001; Gu et al., 1988; Keely et al., 2005). 
It is therefore reasonable to assume that the duration of experiments were not long enough to 
observe the chitosan effect.  
Another factor is pH. It has been shown that chitosan loses its effects in a pH environment 
higher than 7.0 (Aungst, 2000). Chitosan has a pKa of 5.5 – 7.0, thus it is deprotonated at a pH 
higher than 7.0. Deprotonated chitosan likely does not act on TJs in rat duodenum (Kotzé et 
al., 1999), where the pH is around 7.8 (Hurst et al., 2007; Martinez et al., 2002). During the 
present study, the pH in the Ussing chamber was reduced by acetic acid (vehicle) or chitosan 
solution. However, since the experimental set-up and buffer was similar to the HT29/B6 and 
Caco-2 cell monolayers, the pH did not seem to interfere in those experiments. In future 
investigations modified chitosan compounds with enhanced mucus adhesion properties like 
chitosan glutamate, trimethyl chitosan or mono-N-carboxymethyl chitosan (Merzlikine et al., 
2009; Thanou et al., 2001a, 2001b) should be tested. Those compounds have been shown to 
affect TER and TJs in vivo and in vitro. 
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8.3 Behavioral experiments 
Based on the in vitro results, in vivo experiments using an animal model of inflammatory pain 
were performed. Since AS006 production had been discontinued and loperamide is already in 
clinical use, the experiments focused on loperamide. Initially, the analgesic effects of i.v. 
loperamide were compared to i.v. morphine sulfate as a positive control (Cho et al., 2013; 
Khalefa et al., 2012; Vann et al., 2009; Wang et al., 1994). In accordance with previous 
reports, morphine sulfate induced higher PPT elevations in inflamed than in noninflamed 
hindpaws. This has been attributed to the functional recruitment of peripheral opioid receptors 
in inflamed tissue (Stein, 1993; Stein et al., 1988a, 2003). Loperamide induced PPT 
evaluations in inflamed but not in noninflamed hindpaws. During the experiments no sedation 
or respiratory depression was observed. The absence of such centrally mediated side effects is 
an indication for the predominant involvement of peripheral opioid receptors at the doses 
tested here. Peripherally mediated antinociceptive effects of i.v. loperamide were also 
observed by others within the same dosage range (Khalefa et al., 2012) but in other animal 
models (Guan et al., 2008; Shinoda et al., 2007). Mortality, sedation or respiratory depression, 
as described with higher doses of i.v. loperamide (10 mg/kg) (Khalefa et al., 2012; 
Niemegeers et al., 1979) were not observed during the present experiments. Loperamide is a 
preferred P-gp substrate (Elkiweri et al., 2009; Shin et al., 2011; Thiebaut et al., 1987b) in 
contrast to morphine (Dagenais et al., 2004; Wandel et al., 2002). This has been proposed to 
underlay the relatively low penetration of loperamide into the CNS. 
Orally administered morphine sulfate and loperamide also induced dose-dependent PPT 
evaluations. Similar to i.v. injections, both compounds produced stronger effects in inflamed 
tissue. The administration of 20 mg/kg morphine sulfate (but not of loperamide) was 
accompanied by slight sedative effects, presumably mediated by central opioid receptors. The 
intensity of the analgesic effect induced by oral morphine sulfate was comparable to that 
observed after i.v. injection. In contrast, a higher dose of oral loperamide was required in 
comparison to the i.v. dosage. This could be due to differential metabolism of the two opioids 
in the liver or to a more restricted ability of loperamide to cross the intestinal barrier. Thus, 
dose-dependent analgesic effects were induced by oral loperamide alone, which is in line with 
the in vitro results. Here, loperamide crossed the intestinal barrier to a certain degree without 
an absorption enhancer.  
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Next, the site of action of loperamide was analyzed using NLXM. This quaternary derivative 
of naloxone is used to distinguish between central and peripheral sites of action of opioid 
receptor agonists (Levitskaia et al., 2009; Lewanowitsch and Irvine, 2002). It is a competitive 
antagonist which binds to mu, delta, and kappa opioid receptors (Zimmerman et al., 1994). 
Due to the quaternary amine, the opioid receptor antagonist activity is reduced in comparison 
to standard antagonist naloxone (Bianchetti et al., 1983). It has a greater polarity and reduced 
lipid solubility, which restricts its passage across the blood brain barrier into the CNS (Brown 
and Goldberg, 1985; Zimmerman et al., 1994). In the non-inflamed paw neither loperamide 
nor NLXM had significant effects. In the inflamed paw, the analgesic effect of loperamide 
was attenuated using 2.5 and 5 mg/kg NLXM. This is in accordance with previous studies 
showing that the analgesic effect of systemically administered loperamide in models of 
inflammatory pain (Khalefa et al., 2012), visceral pain (Labuz et al., 2007), or muscle pain 
(Sánchez et al., 2010) can be antagonized by NLXM. Sánchez et al. and Khalefa et al. have 
shown that the antinociceptive effect of intraperitoneally (Sánchez et al., 2010) and i.v. 
(Khalefa et al., 2012) administered loperamide was completely antagonized by NLXM 
administered systemically before the agonist. In contrast, intracerebroventricular (i.c.v.) and 
intrathecal (i.t.) NLXM did not abolish the antinociceptive effect of i.v. loperamide (Khalefa 
et al., 2012). Taken together, these findings support the notion that systemically administered 
loperamide (at the doses used here) does not cross the blood brain barrier and produces 
antinociception by activating peripheral opioid receptors in inflamed tissue. However, no 
effects of NLXM at high doses (10 mg/kg) were observed, which may be explained by a dual 
(inverted U-shape curve) dose-effect relationship (e.g. by ligand-induced conformational 
changes of opioid receptors). Such phenomena have been observed frequently in various G-
protein coupled receptor systems and were extensively reviewed elsewhere (Calabrese, 2009).  
 
The next aim of in vivo experiments was to enhance the analgesic effects of orally applied 
loperamide by chitosan. Although this was found in pilot experiments, replication trials with 
larger groups of animals did not yield statistically significant effects. All of the previous 
experiments had shown that the analgesic effect of loperamide alone vanished after 60 min, 
irrespective whether it was applied i.v. or orally. This was also reported by others (Khalefa et 
al., 2012). Further experiments are necessary to determine the optimal interval between oral 
chitosan and opioid administration, the optimal anatomical locus of application (e.g. stomach, 
duodenum, lower intestine) and other (e.g. hydrophilic) opioid enhancer combinations. 
Following the “3R” (“Refine, Reduce, Replace”) concept to decrease the number of animal 
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experiments, the in vitro setup may help to refine such in vivo experiments, e.g. by 
extrapolating dosages. However, further in vivo studies are undoubtedly necessary, since the 
in vitro system is an artificial environment which cannot properly mimic the in vivo situation.  
In summary, loperamide is applicable as a peripherally acting opioid analgesic in a model of 
inflammatory pain in rats. The good correlation of intestinal drug permeability between rats 
and humans (Cao et al., 2006) makes loperamide a promising analgesic drug for clinical 
application. Absorption enhancers such as chitosan may offer new possibilities for 
peripherally acting opioids. Chitosan is effective in vitro. Epithelial permeability 
enhancement by chitosan appears to be more effective for hydrophilic opioids (AS006) than 
for lipophilic ones (loperamide). Future in vivo studies should investigate different 
formulations and application schedules, and address the effects of chitosan on the 
antinociceptive efficacy of hydrophilic opioids. 
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